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The ETS family of transcription factors is known to play an essential role in 
hematopoietic and vascular development. One such factor that is widely expressed in 
all vascular beds and almost all hematopoietic lineages, extending from long term 
hematopoietic stem cells to terminally differentiated peripheral blood cells, is Fli1. 
Global deletion of Fli1 leads to embryonic lethality at E11.5 due to dramatic 
hemorrhaging caused by poor vascular integrity and platelet dysfunction. The role of 
Fli1 in adults has been explored in several different cells types ranging from 
megakaryocytes to B and T cells. It has also been implicated in transcriptional 
regulation of hematopoietic stem and progenitor cells through combinatorial analysis, 
however its exact contribution to stem cell maintenance and function remains unclear. 
We hypothesized that Fli1 plays a dual role in regulating both the seed and the soil – 
specifically hematopoietic stem cell (HSC) function in a cell autonomous manner as 
well as the niche required for nurturing these cells.  
In the first study, we focused our attention on the cell autonomous function of 
Fli1. We found that global deletion of Fli1 in adults leads to lethality as a result of 
complete peripheral blood failure in addition to aberrant vasculature. Using the cre-lox 
system and various transplantation strategies, we identify Fli1 as one of the critical 
regulators of adult hematopoietic stem cell function. Specific deletion of Fli1 in the 
hematopoietic compartment alone is sufficient to induce significant reduction in 
peripheral blood counts, accompanied by hemorrhage, resulting in lethality. On further 
inspection, Fli1∆/∆ HSCs are unable to expand ex-vivo or engraft in a competitive 
 
 
setting. Additionally, Fli1 is essential for hematopoietic reconstitution post radiation 
and its deletion abolishes the ability of stem cells to reconstitute the bone marrow and 
contribute to peripheral blood lineages. ChIP-seq analysis demonstrates Fli1 
occupancy in a majority of essential hematopoietic gene enhancers and promoters. By 
correlating Fli1∆/∆ HSC RNA-seq analysis with the ChIP occupancy data we can 
conclude that Fli1 is, in fact, one of the master regulators of the HSC transcriptional 
program essential to maintain the balance between self-renewal and differentiation. 
Taken together, our results indicate that Fli1 is required for maintenance of HSC 
homeostasis and function, making it one of the unique transcription factors to play a 
critical role in HSC function in adults as well as during development. 
In the second set of studies, we interrogated the role of Fli1 in the endothelial 
niche and more specifically in the maintenance of endothelial homeostasis. We found 
that Fli1, by itself, is not essential for maintaining endothelial fate during homeostasis 
or under stress. We hypothesized that this may be due to redundancy between Fli1 and 
Erg, another ETS factor that shares significant homology with Fli1. Endothelial 
specific deletion of both Fli1 and Erg results in lethality, 12 days post induction due to 
disruption of vascular homeostasis and the formation of multiple thrombi in the liver. 
Fli1 and Erg deletion results in a reduction in a variety of vascular genes in multiple 
vascular beds in addition to organ specific vascular signatures. The disruption of 
vascular homeostasis is accompanied by a significant reduction in platelet numbers in 
peripheral blood. In vitro analysis of the endothelial deletion reveals a complete loss 
of vascular identity with significant reduction in VE-Cadherin and CD31 expression 
accompanied by a concomitant increase in mesenchymal marker α-SMA. 
Taken together, these studies uncover a critical role for Fli1 in maintaining 
homeostasis in both endothelial cells as well as hematopoietic stem cells. 
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CHAPTER 1: INTRODUCTION 
 
1.1 THE SEED AND THE SOIL 
 
The “seed and the soil” is a concept that has transcended generations. First 
proposed in the 1800s, it emphasized the importance of the environment in outcomes 
for metastasis (Paget, 1889). The application of this concept is not limited to 
physiology at a cellular level but transcends society itself. The environment that a 
child is nurtured in has long term effects on his or her success in society. So be it at 
the level of a nucleus where a somatic cell is reprogrammed into an omnipotent stem 
cell or at the socioeconomic level of impacting education and career tracks, the 
external cues one experiences are as important, if not more important than the internal 
signals that govern its function.  
 
One of the most tightly regulated microenvironments in the body is the bone 
marrow (Heissig et al., 2002; Heissig et al., 2005; Morrison and Scadden, 2014; Yu 
and Scadden, 2016). It is unique in its ability to orchestrate the continuous generation 
of the hematopoietic system that supports the everyday functions of an organism and 
generates close to 100 billion cells daily (Dzierzak and de Pater, 2016). The 
hematopoietic system consists of a wide variety of different lineages with specialized 
functions (Figure 1.1). These can be broadly classified into three categories – 
Erythrocytes that are mainly involved with oxygen and carbon dioxide transport, 
megakaryocytes and platelets involved in the wound healing response and clotting 
cascade and leukocytes that coordinate immunity. The generation of this wide array of 
cells is initiated by a single cell at the top of the hierarchy – the hematopoietic stem 
cell (HSC).  
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Figure 1.1 Overview of hematopoietic development into various terminally 
differentiated cell types (H.L. David et al., 2012) 
 
The HSC is unique among other adult stem cells due to the fact that it is easy 
to isolate from the bone marrow, it is robust in being able to withstand flow sorting 
added to the fact that transplantation of these cells, even at a clonal level, can 
reconstitute the entire hematopoietic system of the organism. These properties have 
enabled extensive studies to understand the mechanisms that govern its capacity to 
self-renew, expand and differentiate depending on the physiological state and 
requirement of the organism. The HSC, despite being a cell with such limitless 
potential, is dependent on the external cues it receives from the niche to maintain the 
balance between self- renewal and differentiation. This concept was first proposed 
back in 1978 by R. Schofield when he hypothesized that the surrounding cells 
determine the fate of the stem cell and hence its location in the tissue is restricted. 
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Figure 1.2 A representative mechanism for HSC self-renewal and differentiation 
from R. Schofield (Yu and Scadden, 2016) 
 
As long as the stem cell is occupying this ‘niche’ it can maintain its identity and 
expansion of these cells require the availability of similar niches that can maintain the 
stem cell in its undifferentiated state (Figure 1.2). Scientists are still interrogating the 
function of different cell types that encompass the niche as well as the molecular 
interactions that regulate the crosstalk between each of these cells and the 
hematopoietic stem cell. 
 
Schofield’s hypothesis at the time lacked strong experimental support. Genetic 
evidence for the role of specific niche cells in hematopoiesis was discovered nearly 
three decades later when osteoblast cells were found to affect HSC homeostasis 
through the Jagged-Notch (Calvi et al., 2003) axis as well as through BMP signaling 
(Zhang et al., 2003). The advent of the cre-lox system (Feil et al., 2009) to spatially 
control genetic manipulation in specific cell types enabled researchers to interrogate  
the role of different cell types in the niche through specific pathways involved in HSC 
regulation.  
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Figure 1.3 The heterogeneity of the HSC niche in the adult bone marrow 
(Crane et al., 2017) 
 
The osteoblastic niche was implicated in regulating HSC self-renewal as well 
as differentiation. Osteoblasts were hypothesized to confer quiescence via the Ang-
1/Tie2 axis and prevent HSC apoptosis during myelosuppressive stress (Arai et al., 
2004). Additionally, BM localization and proximity to the endosteum was implicated 
to play a role in HSC ageing (Kohler et al., 2009). Increased distance from the 
endosteum seemed to induce a loss in polarization in aged mouse HSC leading to a 
concomitant impairment in supporting hematopoiesis. Real time imaging of the BM 
suggested that HSCs have a tendency to localize closer to the endosteum (Xie et al., 
2009). Over the past several years, a variety of different cell types have been 
implicated to play a critical role in regulating different functions of hematopoiesis 
(Figure 1.3).  
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The first niche cell bolstered by elegant and convincing genetic proofs proven 
to play a role in self-renewal and differentiation of authentic HSC is specific subsets 
of the endothelial cells within the hematopoietic organs. Studies from our group and 
others have established an essential role for the vascular niche in maintaining HSC 
homeostasis in vivo (Avecilla et al., 2004; Heissig et al., 2002; Hooper et al., 2009; 
Kiel et al., 2005; Kimura et al., 2011). CXCL12, Jagged1, VEGFR2, Jagged2 are just 
a few of the factors that have been shown to coordinate their effect on the HSC 
through the vascular niche (Guo et al., 2017; Hooper et al., 2009; Poulos et al., 2013). 
In addition to their role in vivo, E4ORF1 modified endothelial cells serve as a robust 
platform to expand and maintain both mouse and human hematopoietic stem and 
progenitor cells in vitro (Butler et al., 2012; Butler et al., 2010; Kobayashi et al., 2010; 
Seandel et al., 2008). BM endothelial cells have been shown to have significant 
potential in maintaining multipotent progenitors in an in vitro setting that are capable 
of engraftment. Recently, it was shown that BMEC transplant can offer 
radioprotection post myeloablative radiation revealing a unique angiocrine profile that 
enables the endothelial cells to support BM recovery (Poulos et al., 2015). All these 
studies point to a critical role for endothelial cells in regulating HSC biology. A 
unique cell type that has its origins linked to the hematopoietic stem cell has been a 
recent addition to the HSC niche. Megakaryocytes have been implicated in  
maintaining HSC quiescence through the secretion of CXCL4, TGFβ1 as well as 
Thrombopoietin (Bruns et al., 2014; Nakamura-Ishizu et al., 2014; Nakamura-Ishizu et 
al., 2015). Megakaryocytes also have a radioprotective role that is critical in mitigating 
radiation damage for HSCs (Zhao et al., 2014).  
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Figure 1.4 Differential Fli1 expression across various cells types – Lung 
endothelial cells, Peripheral Blood (PB) Differentiated cells, Bone marrow (BM) 
progenitors (MEP – Megakaryocyte-erythroid progenitor, CMP – common 
myeloid progenitor, GMP – Granulocyte Monocyte progenitor, KLS – 
cKit+LineagenegSca1+, LT-SLAM – KLS CD150+CD48-) 
 
Having observed the importance of different cell types in HSC maintenance, 
we decided to explore the role of a factor that may be critical in HSC regulation from 
the cell autonomous perspective as well as from the niche setting. To this end, we 
interrogated the role of Fli1, which is expressed at high levels in endothelial cells, 
megakaryocytes as well as HSCs (Figure 1.4). 
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1.2 EMBRYONIC HEMATOPOIESIS 
 
HSC functions can be broadly classified into three main categories – 
specification, self-renewal and differentiation. The balance between these however, is 
temporally and spatially regulated. During development the transcriptional machinery 
is focused initially on specification followed by self-renewal and differentiation aimed 
at generating the complete hematopoietic system for the embryo as it grows. During 
adulthood, this balance shifts towards self-renewal and maintenance. The primary 
functional difference between an adult HSC and a fetal HSC is that during 
homeostasis an adult HSC is not required to reconstitute the entire hematopoietic 
system and is predominantly quiescent which is why a lot of the factors that are 
essential for HSC function during development do not carry over their effect to 
adulthood.  
 
During development, hematopoiesis occurs in distinct waves; however, the 
generated hematopoietic cells can be classified into two categories – primitive  
hematopoiesis which refers to the hematopoietic cells generated during development 
which generally do not last throughout the lifespan of the organism and begin to 
disappear postnatally and definitive hematopoiesis which encompasses the HSC pool 
that is generated during development which gives rise to the entire hematopoietic 
system that will maintain homeostasis throughout the lifespan of the organism 
(Medvinsky et al., 2011). The first hematopoietic cells emerge in the extraembryonic 
yolk sac even before initiation of circulation (Lux et al., 2008), by about E7.5 days 
post coitus (dpc) followed by the allantois and the placenta at E9.5 (Figure 1.5B). By  
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Figure 1.5 A – Different sites of hematopoiesis in the developing embryo, 
B. Timeline of hematopoietic activity during development in the mouse and man 
(Costa et al., 2012; Rieger and Schroeder, 2012) 
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E10.5, hematopoietic cells are detected in the aorta-gonad mesenephros (AGM) region 
as well as the umbilical and vitelline arteries. There is a steady transition in 
hematopoietic potential as new sites become active (Cumano and Godin, 2007) 
however before E10.0 the yolk sac is the predominant site for hematopoiesis giving 
rise to primitive erythroid, myeloid and lymphoid progenitors(Palis et al., 1999; Yang 
et al., 2014). The yolk sac was earlier thought to be one of the only embryonic sites of 
hematopoiesis until clear evidence from chick-quail experiments showed the absence 
of any donor contribution pre-circulation (Dieterlen-Lievre, 1975). The AGM region 
is predominantly responsible for de-novo HSC generation (Medvinsky and Dzierzak, 
1996; Taoudi and Medvinsky, 2007) however the exact contribution of the other 
hematopoietic sites to definitive hematopoiesis is still controversial. The expression 
profile of the HSC lineage has been extensively studied in order to identify markers 
distinguishing the HSCs at every stage of their development(Chen et al., 2009; 
Liakhovitskaia et al., 2014; Rybtsov et al., 2011; Taoudi et al., 2008; Taoudi and 
Medvinsky, 2007). Currently, the profile of CD45+VE-Cadherin+cKit+CD34+CD150- 
is well accepted to identify the small HSC pool in the AGM from E10.5-E12.5. Post 
emergence from the AGM, the HSCs home to the fetal liver where they expand and 
repopulate extensively, steadily acquiring the more adult KLS phenotype till birth of 
the mouse (Figure 1.5A, 1.6). Close to birth the HSCs home to the BM where they 
remain throughout the life of the mouse.  
 
1.3 ADULT HEMATOPOIESIS 
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Figure 1.6 A schematic of definitive HSC specification in the developing embryo 
(Medvinsky et al., 2011) 
 
The adult HSC sits at the top of a hierarchy that enables multiple rounds of 
amplification before arriving at terminally differentiated peripheral blood cells (Figure 
1.7). Every stage of this hierarchy results in a certain degree of lineage restriction 
(Akashi et al., 2000; Kondo et al., 1997; Miyamoto et al., 2002). The bulk of the  
expansion of the HSC pool occurs during embryonic development with minimal 
divisions occurring once the mouse is mature. This applies to both the mouse as well 
as the human hematopoietic system. The human hematopoietic system bears close 
resemblance to the mouse however the degree of enrichment in the stem cell pool that 
can be obtained purely based off the surface expression profile of certain populations 
is much lower (Majeti et al., 2007; Notta et al., 2011). On the one hand this may be 
due to an incomplete expression profile for optimal human HSC enrichment; however, 
on the other hand the read out for enrichment is by xeno transplants into humanized 
mouse models which may underestimate the degree of  stemness harbored by the 
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Figure 1.7 Adult hematopoietic hierarchy (Rieger and Schroeder, 2012) 
 
transplanted cells (McDermott et al., 2010; Rongvaux et al., 2011; Strowig et al., 
2011). 
 
A large number of factors have been implicated in regulating HSC function. 
These range from epigenetic modifiers such as Bmi1 (Lessard and Sauvageau, 2003; 
Park et al., 2003) and cell cycle regulators such as p57 (Matsumoto et al., 2011; Zou et 
al., 2011) to signaling proteins such as Lnk (Ema et al., 2005) and Stat5 (Wang et al., 
2009) but in terms of transcriptional regulation a heptad of Transcription Factors 
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(Runx1, Gata2, Fli1, Erg, Scl, Lmo2, Lyl1) have been shown to be important for 
combinatorial interactions necessary for maintaining HSCs in mice as well as humans 
(Beck et al., 2013; Pimanda et al., 2007; Wilson et al., 2010). Despite having lethal 
embryonic phenotypes most of these genes do not exhibit any critical role in HSC 
function during adult homeostasis. There is a degree of redundancy that allows the 
loss of function of one or more of these factors during adulthood. One drastic example 
of this in the mouse is Runx1 which during development is only required for 
specification and not thereafter despite being expressed in a majority of hematopoietic 
cells throughout the life of the organism (Chen et al., 2009). Of the remaining heptad, 
Lyl1 and Scl are highly homologous and during adult homeostasis, loss of either of 
these factors exhibit mild phenotypes however HSCs with both factors absent show 
significant reduction in self-renewal and overall functionality (Capron et al., 2006; 
Curtis et al., 2004; Souroullas et al., 2009). Gata2 is one of the factors that has been 
shown to play a role during development as well as homeostasis (de Pater et al., 2013; 
Lim et al., 2012) and both Erg and Fli1 have been shown to play a role in endothelial 
specification and hematopoiesis during development. 
 
Of the 7 TFs, the role of Fli1 has not been explored in the context of HSCs in a 
cell autonomous manner, developmentally or during adulthood in great detail. Fli1 
was first discovered due to its role in erythroleukemia (Ben-David et al., 1990; Ben-
David et al., 1991; Watson and Seth, 1992). Studies have shown that dysregulation of 
Fli1 results in a shift in the balance between mega-erythroid lineage (Starck et al., 
2010). Global deletion of Fli1 in mice leads to embryonic lethality at E11.5 (Hart et 
al., 2000) due to hemorrhage and loss of vascular integrity.  Fli1 function has been 
restricted to endothelial and megakaryocyte lineages developmentally as well as other 
more differentiated hematopoietic cell types in adults. 
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1.4 ENDOTHELIAL HOMEOSTASIS AND VASCULAR HETEROGENEITY 
 
The development of the vasculature is one of the earliest events during 
embryonic development and plays a critical role in the development of the embryo. 
Vasculogenesis refers to the de novo formation of the first endothelial cells from 
mesodermal precursors which ultimately form the vascular plexus (Hatzopoulos et al., 
1998). The subsequent expansion and remodeling of these primitive blood vessels is 
termed angiogenesis(Tirziu and Simons, 2009). It is well accepted that the 
vasculogenesis occurs during development at E7.5 (Coffin et al., 1991). Extra-
embryonic mesodermal cells in the yolk sac aggregate to form blood islands that give 
rise to the first endothelial and hematopoietic lineages expressing CD34, CD31 and 
QH1 while intra-embryonic endothelial cells form from precursors expressing 
SCL/TAL1 (Drake et al., 1997). Flk1 or VEGFR2 is one marker that the intra and 
extra-embryonic endothelial cells have in common. These cells continue to expand 
and remodel forming the paired dorsal aortas at E8.0 which precedes the start of 
circulation at E9.0. Endothelial cells and hematopoietic cells are closely related in 
their ontology (Medvinsky et al., 2011) and share a large number of genes. Definitive 
hematopoiesis transitions through two basic phases, specification and expansion 
during development followed by homeostasis and maintenance postnatally while 
endothelial cells are involved in organ development during development, postnatally 
until the organism reaches adulthood. In adulthood, most endothelial cells are 
quiescent (Dejana et al., 2007) due to which a large number of factors that are required 
during development and postnatally are found to be redundant during adulthood. This 
factor holds true for HSCs however not for the rest of the hematopoietic system since 
it is actively generating billions of cells on a daily basis.  
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Figure 1.8 The role of endothelial cells during angiogenesis (Ramasamy et al., 
2015) 
 
Despite their dormant state, endothelial cells do possess the ability to respond 
to stimuli and reinitiate angiogenesis if the need arises in the event of an injury (Ding 
et al., 2010; Ding et al., 2011). There are a few physiological and non-physiological 
conditions during which endothelial cells are activated and essential. Tumor 
angiogenesis plays a critical role in progression of cancer be it in solid tumors or 
leukemias (Carmeliet and Jain, 2000; Jain, 2014). Our understanding of endothelial 
cell function is always evolving and has come a long way since the classical role that 
endothelial cells were thought to perform which was carrying blood and nutrients to  
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Figure 1.9 Heterogeneity in capillary wall morphology (Cleaver and Melton, 2003) 
 
various organs of the body. There is increasing evidence that ECs not only perform an 
essential transport network role but are actively involved in growth, differentiation and  
repair throughout the body. Endothelial cells have been shown to be actively involved 
in tissue morphogenesis through the secretion of paracrine or ‘angiocrine’ factors  
 (Figure 1.8). This maybe in the form of secreted factors such as Wnt, BMP and HGF 
(Ding et al., 2010; Wertheimer et al., 2018) or through surface receptor ligand 
interactions like Jagged1 and Jagged2 (Poulos et al., 2013).  
 
The above findings revealed a gene expression profile that was distinct 
depending on the vascular bed involved. The heterogeneity of endothelial cells in 
inherently not a novel concept (Ribatti et al., 2002) however our understanding of the 
degree of heterogeneity that exists in the vasculature has changed dramatically. There 
are multiple levels of heterogeneity that exist in the vasculature. The first being the  
difference between lymphatic vessels and blood vessels. Within this there is the 
differentiation between large vessels encompassing arteries and veins and small 
vessels or capillaries. The most evident heterogeneity is visible from the 
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morphological perspective. EC capillaries vary from organ to organ in terms of their 
morphology and may be continuous as seen in fat and muscle or fenestrated in the case 
of intestinal or kidney glomeruli capillaries or discontinuous as seen in the liver, 
spleen and BM (Figure 1.9). Another level of heterogeneity is dictated by the spatial 
positioning of endothelial cells namely organ-based heterogeneity. Functional 
heterogeneity based on the organ type centers around the gene expression profiles of 
ECs in different vascular beds (Nolan et al., 2013) and enables them to react 
differently to external stimuli and orchestrate tissue repair in the case of damage. 
Understanding these subtle differences in the vasculature is key to being able to 
exploit the untapped potential of endothelial cells in manipulating disease conditions 
or making an environment hostile for malignancies and goes back to the concept of the 
seed and the soil. Recent literature has revealed that tumors hijack the vasculature not 
only for nutrients and oxygen but to form a malignant niche capable of sustaining 
growth as well as providing an immune privileged environment protecting the tumor 
from the host’s immune system as well as chemotherapy (Cao et al., 2014; Cao et al., 
2017). Most cancer treatments are targeted to mutations and cell intrinsic factors that 
cripple tumor cells however overlooking the role of the vascular niche from an organ 
specific perspective in the case of primary tumors as well as metastasis might be one 
of the biggest reasons for the inefficiency in cancer treatment and the cause for 
relapse. 
 
 Studies over the past two decades have attempted to improve our 
understanding of the various signaling pathways that orchestrate vascular 
development, heterogeneity and function. The ETS and FOX family of transcription 
factors have been shown to be intricately involved in transcriptional regulation of 
endothelial specification, angiogenesis and homeostasis (Dejana et al., 2007). One of 
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the earliest factors that has a very specific endothelial expression profile is VEGFR2 
or Flk1. Flk1 expression is at its peak during vasculogenesis and angiogenesis and 
deletion of this receptor is embryonic lethal between E8.5 to E9.5 dpc due to defects in 
the development of hematopoietic and endothelial cells (Shalaby et al., 1995). Flk1 
deletion results in the absence of yolk sac blood islands as well as organized blood 
vessels at E7.5 along with significantly reduced hematopoietic progenitors. Flk1-/- ES 
cells were unable to contribute to any endothelial lineages, primitive and definitive 
hematopoiesis in mouse chimeras demonstrating the essential role of VEGFR2 in 
endothelial development (Shalaby et al., 1997). Another essential vascular marker is 
VE-Cadherin or Cdh5 which leads to embryonic lethality at E9.5 similar to VEGFR2, 
due to impairment of remodeling and maturation in the vascular plexus while also 
inducing EC apoptosis due to absence of downstream signaling to critical survival 
signals – Akt and Bcl2 (Carmeliet et al., 1999). Tie2, Flt1, Ang1, Ang2, VEGF-A, 
Dll4 are just some of the factors that play key roles in endothelial function.  
 
A lot of research has focused on understanding the mechanisms governing 
endothelial function during development and in adult however given the quiescent 
nature of the majority of adult vasculature the transcription factors that regulate 
vascular homeostasis in adults are not known. Most ETS and FOX factors that have 
drastic vascular permeability or specification defects exhibit mild phenotypes in adult. 
To this end, we interrogated the role of two ETS factors, Fli1 and Erg, with 
developmental roles in endothelial stability and that have been shown to be required 
for direct conversion of amniotic cells to an endothelial fate (Ginsberg et al., 2012; 
Schachterle et al., 2017) in the context of adult endothelial homeostasis. Identifying 
the master regulators of endothelial cell fate and vascular homeostasis would give us a 
tractable platform to interrogate which pathways play key roles in core endothelial fate 
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regulation as well as understanding the underlying mechanisms involved in vascular 
organ heterogeneity. 
 
1.5 FLI1 AND THE ETS FAMILY OF TRANSCRIPTION FACTORS 
 
Friend Leukemia virus integration-1 or Fli1 was first identified through its 
involvement in Friend murine leukemia virus (F-MuLV) induced erythroleukemia. 
Tumors and cancer is a common theme with respect to the discovery of several genes 
and Fli1 is no different. It was found that the Fli1 locus is a pro-viral integration site in 
75% of the F-MuLV induced erythroleukemia and very specific in terms of its effect 
on the erythroid lineage since the myeloid and lymphoid tumors did not show any 
integration bias. This specificity not only extended to the hematopoietic lineage but 
also the type of virus with other Friend virus complexes, FV-A and FV-P, not showing 
the same locus rearrangement as seen with the F-MuLV (Ben-David et al., 1990; Ben-
David et al., 1991). A year later, Fli1 was also found to be involved in Cas-Br-E 
MuLV-Induced Non-T, Non-B-Cell Leukemias (Bergeron et al., 1992) and identified 
in the human genome showing extensive homology to Erg (Watson and Seth, 1992), 
another gene in the ETS family of transcription factors. Fli1 dysregulation has been 
detected in a wide variety of non-physiological conditions (Hart et al., 2000; Li et al., 
2015). One in particular has contributed to the majority of the research on Fli1 is 
Ewing Sarcoma. Fli1 is part of a potent translocation t (11;22) (q24; q12) which 
generates a fusion protein EWS-Fli1 in about 85% of Ewing Sarcomas (Delattre et al., 
1992). EWS-Fli1 uses the 3’ ETS DNA binding domain of Fli1 in conjunction with 
the 5’ transactivation domain of the EWS to enable a gene expression profile that 
triggers a strong transformation phenotype (May and Denny, 1993).  
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Fli1 is a member of the E26 transformation specific (ETS) family of 
transcription factors.(Leprince et al., 1983) The ETS family of TFs play a critical role 
in several physiological processes specifically in terms of endothelial and 
hematopoietic lineages (Birdsey et al., 2008; Craig et al., 2015; Kataoka et al., 2011; 
Lee et al., 2011; Lee et al., 2008; Liu et al., 2012; Loughran et al., 2008; Wei et al., 
2009). Ets-1 was the first ETS factor to be discovered as a viral oncogene in E26 avian 
leukemia (Leprince et al., 1983). Based on homology, 26 ETS genes have been 
identified in the mouse genome with 27 being identified in humans (Figure 1.10). The 
ETS factors carry out diverse functions with some family members being exclusively 
transcriptional activators while others perform primarily repressor function but the 
majority play a dual role depending on the spatial and temporal context. All members 
of the ETS family share one common feature – a highly conserved DNA binding 
domain called the ETS domain that is characterized by a winged helix-turn-helix 
containing three α-helices and four β-sheets which specifically binds to the DNA 
sequence 5’-GGA(A/T)-3’. Despite this conserved moiety, structural and 
conformational differences in ETS factors regulate their DNA binding by recognizing 
DNA motifs over 11-bases around the GGA site. An additional feature present in a 
subset of the ETS factors is the pointed domain. The pointed domain is a feature that 
regulates homotypic and heterotypic interactions between ETS factors and other 
binding partners that regulate the transcriptional profile of the gene. The pointed 
domain can also modulate the type of transcriptional activity targeted by the factor 
switching between repression and activation of genes in different cell types. 
 
Given the large number of ETS factors and their co-expression in several cell 
types, there are different mechanisms that ensure specificity in terms of their function. 
The first layer of specificity is through structural differences that change the DNA  
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Figure 1.10: The ETS family of transcription factors (PD – pointed domain, TAD 
– transactivation domain, ND – negative domain, RD – repression domain, ETS – 
DNA binding domain) (Charlot et al., 2010) 
 
binding profile through differential affinity to various sequences. The second layer is 
regulated through the binding of co-factors. The pointed domain is one feature that 
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enables diverse interactions with different binding partners dependent on the cell type 
and gene expression profile of binding partners within different cells. Both the above 
mechanisms are further modulated through post translational modifications. 
Phosphorylation, one of the most common PTM, generally occurs on a serine, 
threonine or tyrosine through serine/threonine protein kinases or via tyrosine kinases. 
The MAPK pathway is a predominant player in regulating ETS factor  
phosphorylation. Other post translational modifications that predominantly target the 
lysine residue are acetylation, sumoylation and ubiquitination. Acetylation is mediated 
by acetyltransferases such as p300 which transfer an acetyl group to the specific 
residue being targeted while histone deacetylases or HDACs carry out acetyl removal. 
HDACs are generally associated with repressor activity and enable recruitment of 
cofactors that trigger transcriptional repression directly or through recruitment of 
subsequent PTM modifying enzymes that enable protein degradation. Sumoylation 
and ubiquitination involve the addition of a SUMO or ubiquitin moiety respectively 
and this is carried out by three enzymes. The E1 enzyme which transfers the moiety to 
the E2 conjugation enzyme which is then attached to the target protein through the E3 
ligase. Ubiquitin modulates the transcriptional activity of its attached proteins directly 
by modulating transcriptional activity and indirectly by modulating the protein 
stability and half-life through proteasome mediated degradation. The SUMO group, in 
addition to modifying transcriptional activity and stability, is unique in terms of its 
ability to modify the cellular localization of its target protein.  
 
Fli1 has two different isoforms in mice while the human variant has 9 different 
isoforms. The major mouse isoform has a coding DNA sequence of 9 exons covering 
1359 nucleotides which translates to a 452 amino acid protein. Fli1 has a large number 
of annotated post translational modifications throughout the protein however three of  
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Figure 1.11 Schematic of murine Fli1 gene representing the 9 exons with the 
location of the pointed domain and ETS DNA binding domain, total protein 
length of 452 amino acids and various post translational modifications identified 
for the protein. 
 
those have been implicated so far with functional significance (Figure 1.11). The 
Serine10 phosphorylation inhibits Runx1 binding essential to switch from an 
undifferentiated state to a differentiated state in murine megakaryocytic cell line 
L8057(Huang et al., 2009). This interaction with Runx1 was facilitated purely through 
amino acids 281-452, essentially exon 9 which covers the bulk of the protein. 
Replacement of the Serine10 with a phosphomimetic moiety significantly disrupted 
the Runx1 interaction confirming the requirement of the PTM to facilitate the switch 
in the cells. The other is a sequential PTM initiated by transforming growth factor β 
(TGFβ) in fibroblasts. Fli1 is phosphorylated at the threonine 312 by protein kinase C 
δ (PKC-δ) in response to TGFβ stimulus(Asano and Trojanowska, 2009). This leads to 
recruitment of p300/CREB binding protein associated factor (PCAF) that acetylates 
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the Lysine380 residue destabilizing the protein and leading to its degradation(Asano et 
al., 2007). 
 
1.6 MOUSE MODELS OF FLI1 
 
The first mouse model of Fli1 had a very minor defect in thymic development 
exhibiting hypocellularity due to dysfunctional prethymic T-cell progenitors (Melet et 
al., 1996). The design of the intended knockout mouse led to the formation of a mutant 
Fli1 from an alternate start site further downstream of the excised region and hence the 
subtle phenotype was not a true reflection of the role of Fli1. In 2000, the first global 
knockout mouse was designed and Fli1 deletion was found to be embryonic lethal at 
E11.5 due to a loss of vascular integrity resulting in cerebral hemorrhage with a 
concomitant reduction in Tie2 (Hart et al., 2000). The Fli1 null embryos were also 
associated with defects in megakaryopoiesis which corelated with a human condition, 
Jacobsen or Paris-Trousseau Syndrome where a region containing Fli1 was 
hemizygously deleted. Fli1 and Erg genes are both characterized by the presence of a 
pointed domain, the ETS DNA binding domain and an N-terminal and C-terminal 
transactivation domain. To get a more mechanistic insight into the role of the C-
terminal binding domain Spyropoulos et al., 2000 designed a specific deletion 
targeting the region just upstream of this domain and found that it closely phenocopied 
the deletion of the entire last exon. Later research expanded on the phenotypes 
exhibited in these two early papers and observed a significant reduction in fetal liver 
cellularity in the mouse embryos. Additionally, E10.0 AGM cells were dysfunctional 
in giving rise to any cells of the megakaryocyte lineage with a concomitant reduction 
in the levels of c-mpl (Kawada et al., 2001).  
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Another mouse model was used to specifically target only the carboxy-
terminal activation domain (Moussa et al., 2010) and resulted in a embryonic lethal 
phenotype with reduced penetrance. These mice had reduced survival viability with 
about 30% dying postnatally. The viable mice have significantly reduced platelet 
numbers and exhibited defects in platelet aggregation and activation and bleeding 
times. Some of the genes dysregulated in the BM and megakaryocyte compartment 
were c-mpl, gpIIb, gpIV and PF4. These mice were a valuable resource given their 
ability to survive to adulthood. Fli1 was found to regulate B cell development and 
Fli1∆CTA mice had significantly reduced splenic follicular B cells and increased 
number of transitional and marginal zone B cells compared to controls (Zhang et al., 
2008). Fli1 was also correlated to pathogenesis in diffuse large B-cell lymphoma, one 
of the most common forms of human lymphoma. A gain of function in the Fli1/Ets1 
locus was found in about 23% of the DLBCL cases that were analyzed (Bonetti et al., 
2013). Fli1 overexpression was also found to dysregulate T-cell development affecting 
the DN to DP transition and inhibiting CD4 expression while increasing CD8 (Smeets 
et al., 2013). Given its impact on lymphoid development, the role of Fli1 was explored 
in the context of lupus and showed strong correlation with hemizygous reduction in 
Fli1 levels resulting in improved disease outcomes in mouse models for lupus 
(Mathenia et al., 2010; Molano et al., 2010; Nowling and Gilkeson, 2006; Richard et 
al., 2013). Fli1 has been shown to play a role in regulating monocyte, macrophage and 
dendritic cell development. The surviving Fli1∆CTA mice had increased numbers of 
HSC and common dendritic cell precursors compared to controls (Suzuki et al., 2013). 
 
The role of Fli1 so far had been explored in the context of non-cell specific 
deletion. With the arrival of the cre-lox technology, specific Fli1 deletion in cell types  
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Figure 1.12 : A. Schematic diagram of targeting construct for inducible Fli1 
mouse. The region of deletion is in the last exon of Fli1 containing the ETS DNA 
binding domain. B. Effect of Fli1 deletion on platelet numbers. C. Effect of Fli1 
deletion on CFU-Mk numbers for 5x104 BM Cells(Dotted line and gray area 
represent mean and SD of control mice). D. Histogram representing percentage 
of multipotent progenitors in the BM (Asterik and NS represent significant 
p<0.05 and not significant). E. Variation in %MEP with Fli1 deletion efficiency 
(Starck et al., 2010) 
 
of interest could be targeted. Not surprisingly the first two cell types to be targeted 
were endothelial cells and hematopoietic cells. The conditional knockout of Fli1 in 
endothelial cells resulted in a very mild vascular defect of increased permeability and 
a slight reduction in VE-Cadherin and CD31 RNA levels (Asano et al., 2010). The 
level of knockout in these mice however did not seem to be adequate. The conditional 
A 
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deletion in the hematopoietic compartment was carried out using the mx1-cre. The 
effect of deletion in the adult partially phenocopied the global deletion with the mice 
experiencing mild thrombocytopenia with a drastic decrease in mature megakaryocyte 
numbers (Figure 1.12). There was an increase in the MEP population by 50% with the 
CMP and GMP compartments not significantly affected. Fli1 deletion induced a block 
in differentiation among the mega-erythroid lineage with mature megakaryocyte 
numbers close to absent. One common observation from both these papers was that 
the efficiency of Fli1deletion was notably lower than what would be expected from 
these cre deleters (Asano et al., 2010; Starck et al., 2010). It is difficult to predict if 
this is to do with genomic accessibility or cre efficiency however it is definitely a 
point to be noted moving forward with inducible mouse models for Fli1.  
  
 Several groups have attempted to elucidate the role of Fli1 in endothelial cells, 
fibroblasts and various terminally differentiated and multipotent lineages of 
hematopoietic cells (Asano et al., 2009; Asano et al., 2010; Mathenia et al., 2010; 
Moussa et al., 2010; Starck et al., 2010; Suzuki et al., 2012; Zhang et al., 2008; Zhang 
and Watson, 2005); however given the redundancy of factors in adult homeostasis 
when compared to embryonic development we decided to interrogate the exact 
function of Fli1 in maintaining hematopoietic homeostasis focusing specifically on the 
HSC compartment.  
We hypothesized that  
 
“Fli1 is essential for maintenance of hematopoietic stem cell 
and endothelial cell homeostasis.” 
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In Chapter 2 of this dissertation, we investigated the role of Fli1 in HSCs, in vivo and 
in vitro using various cre lines and animal models so as to ablate Fli1 in both a spatial 
and temporally controlled manner. We show that Fli1 is unique in its functional 
relevance in both development as well as adult homeostasis making it indispensable to 
HSC specification, self-renewal and homeostasis. In Chapter 3, we explored the role 
of Fli1 in endothelial homeostasis and show that in conjunction with another ETS 
factor, Erg, Fli1 is essential for maintenance of endothelial fate and is required for 
survival. 
 
1.7 SIGNIFICANCE 
 
The hematopoietic system has several unique features that have enabled 
research in this field to progress in leaps and bounds. First, the ability to transplant 
hematopoietic stem cells that are capable of reconstituting the entire hematopoietic 
system of the host has pushed new frontiers in terms of regenerative medicine 
(Kiernan et al., 2017). Stem cell transplantation has become a routine practice for the 
treatment of hematological disorders as well as malignancies following myeloablative 
therapies to deplete the host bone marrow. Secondly, the ease of acquiring these 
precious reconstitution units has aided in researching HSCs. The discovery of factors 
that trigger the mobilization of HSCs from the BM into circulation such as granulocyte 
colony-stimulating factor (G-CSF) and AMD3100 (Suárez-Álvarez et al., 2012) has 
only added to the ease of collecting these cells. Lastly, the ability of these cells to 
withstand the stress of sorting has allowed them to be studied in great detail and 
separated extensively based on surface marker expression so as to narrow down the 
exact expression pattern that distinguishes these cells from their subsequent progeny. 
Despite having all these advantages, there still are a large number of looming 
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questions for the successful isolation, maintenance, expansion and transplantation of 
these cells (Anand et al., 2017; Kiernan et al., 2017; Wagner et al., 2014). Further 
research is required to minimize engraftment failure as well as post-transplant 
infections. Understanding the mechanisms that regulate these key features will enable 
a significant increase in efficiency of transplantation. The processes that are involved 
in current transplantation settings are 
 
- Isolation and storage of transplantable HSPCs 
- Expansion of the isolated HSPCs 
- Myeloablation/pre-conditioning of the host for transplantation 
- Determination of the quality and quantity of HSPCs to be transplanted  
- Post transplantation monitoring to ensure donor engraftment 
- Monitoring for post-transplant infections 
- Monitoring for donor cell rejection or Graft vs host disease 
 
Each of the steps mentioned above has the potential to be improved from an 
efficiency point of view. Isolation of a small number of the exact cells required for 
transplantation with a minimally invasive method without significant side effects on 
the donor requires a thorough understanding of the mechanisms that govern stem cell 
mobilization as well as the exact surface marker profile for identifying the number of 
HSCs present in every isolate. Having the tools for long term storage of these cells 
without affecting their viability or potency requires an understanding of the 
mechanisms that govern stem cell maintenance and homeostasis so as to trigger a 
quiescent state in the cells before storage. Expansion and manipulation of these cell 
types in situations where cell numbers are not adequate for transplantation requires an 
in depth understanding of the interactions of the HSCs with the BM niche so that they 
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can be manipulated to expand the pool of HSCs without triggering differentiation into 
more lineage restricted progenitors. Understanding the mechanisms governing 
engraftment and homing would allow a quicker recovery from the myeloablation 
which itself needs to be optimized. Devising a pre-conditioning regiment that would 
allow specific homing without rendering the host immunocompromised as well as 
protecting the host from infections and GVHD would represent a breakthrough in the 
field of regenerative medicine. What is clear is that despite all the research that has 
been done thus far, there is still a long way to go in understanding the mechanisms that 
govern HSC behavior in different scenarios and to this end we intend to interrogate 
one of the possible master regulators of HSC biology – Fli1 may govern various 
mechanisms that play a role in each and every aspect of HSC function. 
 
The notion that there exists a single stem cell at the top of the hierarchy in the 
hematopoietic system was proposed back in 1961 by some pioneering research by Till 
and McCulloch. The advent of the colony forming units in the spleen as a measure of 
the stem cell capacity of HSCs marked the beginning of quantitative hematopoietic 
assays (Becker et al., 1963; Siminovitch et al., 1963; Till and McCulloch, 1961). The 
establishment of clonal assays in transplantation settings to examine the self-renewal, 
clonogenicity and lineage contribution enabled researchers to interrogate the 
‘stemness’ of HSCs based on surface marker expression. This triggered an array of 
publications claiming the ability to enrich the stem cell population based of marker 
expression (Kiel et al., 2005; Kondo et al., 1997; Morrison and Weissman, 1994; 
Osawa et al., 1996a; Osawa et al., 1996b). In-vivo transplantation provided functional 
readouts for each aspect of HSC function. Primary transplants enabled assessment of 
HSC contribution to multilineage engraftment and self-renewal capacity. Serial 
transplantation served as a more robust readout to claim HSC self-renewal. The 
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frequency of HSCs in a given population could be determined by the limiting dilution 
assay (Szilvassy et al., 1990). The murine system allowed for these robust readouts. 
Additionally, the generation of genetically modified immunocompromised humanized 
mice enabled the interrogation of the stem cell functionality of human stem and 
progenitor cells in a murine system (McDermott et al., 2010).  
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CHAPTER 2: FLI1 IS ESSENTIAL FOR HEMATOPOIETIC STEM CELL 
SPECIFICATION, MAINTENANCE AND FUNCTION 
 
2.1 INTRODUCTION 
 
Fli1 has been shown to be essential during development. Global deletion of 
Fli1 results in embryonic lethality at E11.5 with the mice exhibiting extensive 
hemorrhage as a result of vascular leakiness and platelet dysfunction (Hart et al., 2000; 
Spyropoulos et al., 2000). The role of Fli1 has been studied extensively in the context 
of megakaryocytes differentiation and platelet formation and more recently in the 
context of other differentiated peripheral blood hematopoietic lineages; however, its 
role in regulating HSC function is still to be explored (Starck et al., 2010). Genomic 
occupancy of Fli1 has been explored, in conjunction with a few other genes that have 
developmental hematopoietic defects, in human cord blood CD34+ cells (Beck et al., 
2013) as well as in the murine multipotent progenitor cell line, HPC7 (Wilson et al., 
2010). This analysis revealed a densely interconnected network of a heptad of 
transcription factors that overlap extensively in their binding purview – Fli1, Erg, 
Gata2, Scl, Lyl1, Lmo2 and Runx1; however their analysis implicated four critical 
genes – Erg, Runx1, Gata2 and Scl to be involved in protein-protein interactions 
necessary to facilitate formation of a transcriptional complex that can bind to DNA. 
This genomic binding data provided valuable information into the binding purviews of 
these genes; however genomic binding does not imply functionality as was seen with a 
majority of the implicated heptad. The caveat to the binding of multiple factors in the 
same genomic location was redundancy and this has been shown for four of the seven 
factors. Gata2 has been shown to be essential in both specification as well as 
expansion of definitive HSCs during development (de Pater et al., 2013) however its 
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exact role in adult HSCs has not been explored. Functional relevance of a factor in 
adult homeostasis has been shown to be quite different compared to development as is 
seen with Scl, Lyl1 and Lmo2 all of which have developmental endothelial and 
hematopoietic phenotypes but do not execute similar roles in adult hematopoiesis. Erg 
is an ETS factor that is closely related to Fli1 and has the most number of binding sites 
among the heptads. It has been implicated to be one of the essential hematopoietic 
transcription factors and has shown to be essential for HSC function during 
development(Kruse et al., 2009; Loughran et al., 2008) as well as in adults (Taoudi et 
al., 2011). The majority of research implicating a role for Erg in HSC maintenance has 
used a mutation Mld2 that silences the transcriptional activity of Erg and so overlooks 
its role in the vascular niche which is essential in maintaining stem cell homeostasis. 
Recent evidence suggests that Erg may indeed play a dual role in regulating the niche 
as well as hematopoiesis however the exact mechanisms governing this are still to be 
explored.  
 
Fli1 is a transcription factor that has been completely overlooked in terms of its 
contribution to HSCs. Earlier research has demonstrated a role for Fli1 in vascular 
integrity during development and extensively in megakaryopoiesis. Previous inducible 
mouse models have revealed difficulties in the efficiency of deleting Fli1 which is 
why we used strong cre deleters – Cdh5 cre (Chen et al., 2009) and the Rosa 
CreERT2. In order to better understand the spatial and temporal role of Fli1 in the 
context of HSCs, we used these cre lines to delete Fli1 at different time points during 
development as well as in adult. By utilizing well designed transplantation schema in 
conjunction with the efficient cre deletion we were able to interrogate the function of 
Fli1 in the context of adult HSC homeostasis as well as its role in hematopoietic 
reconstitution.  
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2.2 RESULTS 
 
2.2.1 Fli1 is essential for definitive hematopoiesis during development 
 
In order to investigate the role of Fli1 in the hematopoietic system we used Fli1f/f mice 
(Starck et al., 2010) and crossed them with Cdh5 (VE-Cadherin) Cre recombinase 
which deletes in the endothelial cells of AGM region of the developing embryo (Chen 
et al., 2009). Fli1f/f; Cdh5 Cre was embryonic lethal with reduction in mendelian ratios 
post E11.5 (Figure 2.1A). Very few embryos were observed after E14.5 and most 
embryos at E13.5 exhibited major hemorrhage or were being resorbed (Figure 2.1B). 
This closely phenocopied the global deletion of Fli1 which demonstrated that the crux 
of Fli1 function is focused on hematopoietic and endothelial lineages despite being 
expressed in a variety of different cell types at much lower levels. In order to assess 
hematopoietic status of these mice, the AGM region was harvested at E11.5. E11.5 
mice did not display any obvious defects visually however on further analysis they 
exhibited significant reduction in total CD45+ cells as well as 
CD45+VECadherin+cKit+ cell numbers (Figure 2.1C). In order to further evaluate the 
cell autonomous function of these cells we sorted them for ex-vivo expansion using 
the robust E4-HUVEC platform (Figure 2.1D) for hematopoietic expansion (Butler et 
al., 2010; Seandel et al., 2008). The Fli1f/f Cdh5 Cre cells exhibited 6-fold lower 
expansion potential compared to the same number of CD45+ cells from Fli1f/f 
littermates. Early definitive hematopoietic cells isolated from the AGM on expansion 
on the E4 HUVEC platform acquire a more fetal stem cell profile expressing CD41 
and Sca1 (Figure 2.1E). Flow analysis of these  
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Figure 2.1 Fli1 deletion in AGM endothelium results in embryonic lethality and 
hematopoietic defects (A) Survival curve for Fli1f/f Cdh5 Cre compared to Fli1f/f 
embryos at time points E11.5 (n=67), E13.5 (n=47), E14.5 (n=26), E18.5 (n=15) (B) 
Representative images of E13.5 embryos with Control Fli1f/f (left) and Fli1f/f Cdh5 Cre 
(Center and Right) showing internal hemorrhage (Center) and absence of heartbeat 
(Right) (C) Quantification of E11.5 AGM CD45+VECadherin+cKit+ percentage 
comparing Fli1f/f to Fli1f/f Cdh5 Cre (*** signifies p< 0.001) (D) Schematic showing 
ex-vivo expansion strategy to assay cell autonomous function of AGM CD45+ cells (E) 
Representative flow plots showing gating scheme to identify expanded fetal KLS. 
Histogram to show reduction in cKit levels in Control vs KO expanded CD45+ cells (F) 
Quantification of total CD45 and KLS expansion in vitro, cKit mean fluorescent 
intensity (** signifies p < 0.01, * signifies p < 0.05) 
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expanded CD45+ cells revealed defective overall expansion as well as a significant 
reduction in cKit+Lineage-Sca1+ (KLS) expansion (Figure 2.1F). Additionally, the  
cKit expression levels of these expanded cells had a clear reduction based on mean 
fluorescence intensity(MFI) (Figure 2.1F). This shift in cKit MFI has been shown 
before (Kimura et al., 2011) and has been correlated with the absence of cKit signaling 
which is known to be essential for stem cell survival. These results indicate that Fli1 
expression in AGM is essential for embryonic development and survival and that the 
Fli1-cKit axis is a critical part of definitive hematopoiesis during development. 
 
2.2.2 Fli1 expression in the hematopoietic system is essential to maintain homeostasis 
 
Given previous evidence that Fli1 deletion using temporally inducible cre 
deletion is not very efficient (Starck et al., 2010) we tested the deletion efficiency of 
the Rosa CreERT2 in adults (>12 week old) using Fli1f/f, Fli1f/f Cre, Fli1f/+, Fli1f/+ Cre 
mice. We found that just 3 injections of tamoxifen were sufficient to induce a lethal 
phenotype in the Fli1f/f Cre mice from Day 7-11 post tamoxifen induction (Figure 
2.2A, B). Seeing this drastic phenotype, we designed a transplant setting to assess the 
cell autonomous effect of Fli1 in the hematopoietic compartment (Figure 2.2C). 
Lethally irradiated CD45.1 mice were transplanted with Fli1f/f Cre or Fli1f/f whole 
bone marrow from littermates. Fli1 deletion was induced 4 months post radiation, after 
confirming engraftment chimerism and peripheral blood counts to ensure homeostatic 
conditions for the mice. CD45.1; Fli1f/f Cre mice phenocopied the global deletion and 
died within 11 days of tamoxifen induction compared to the control transplants that 
were healthy (Figure 2.2D). The Fli1 deleted mice had internal bleeding as well as 
significant reduction in peripheral blood counts with platelets counts dropping 
drastically (Figure 2.2E). The importance of Fli1 in megakaryopoiesis and  
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Figure 2.2 Fli1 is required for hematopoietic homeostasis in adults (A) Mouse 
schematic showing deletion strategy to assess global deletion of Fli1 in adult mice (B) 
Survival cure for global deletion of Fli1 using Rosa CreERT2, experimental cohorts 
compared Fli1f/f, Fli1∆/∆, Fli1f/+, Fli1∆/+ Cre mice (C) Mouse schematic showing 
transplant strategy to elucidate the role of Fli1 in hematopoietic cells (D) Survival curve 
for transplanted CD45.1 mice with Fli1f/f or Fli1f/f Cre BM (E) Peripheral blood counts 
(WBC – White blood cells, RBC – Red blood cells, Platelets, HGB – Hemoglobin, HCT 
– Hematocrit) of Fli1f/f vs Fli1∆/∆ post deletion (*** signifies p<0.001, ** signifies 
p<0.01, * signifies p<0.05) 
 
thrombopoiesis has been well studied however the global drop in both WBC and RBC 
counts has not been shown before. We account this drastic platelet drop to deletion 
efficiency achieved with the Rosa CreERT2 mice which compared to the MX1-cre in 
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the context of this gene is much more effective. Taken together these results show that 
Fli1 is a critical regulator of hematopoietic homeostasis and essential for survival. 
 
2.2.3 Fli1 regulates stem cell function in a cell autonomous manner 
 
Having observed complete peripheral blood failure in the Fli1 deleted 
transplanted mice we next analyzed the bone marrow to examine the cause of this 
hematopoietic effect. There was a significant reduction in bone marrow cellularity that 
was reflected in bone marrow counts (Figure 2.3A). As expected the drop in peripheral 
blood levels triggered a spontaneous expansion in the HSC compartment showing a 4-
fold increase (Figure 2.3B) in KLS multipotent progenitors (cKit+Sca1+Lineageneg). 
Given the absence of functional data on the role of Fli1 in HSCs we interrogated the 
functionality of this KLS pool in the BM. We isolated the KLS cells from the deleted 
mice and expanded them in the E4-HUVEC system (Figure 2.3C) used earlier for the 
AGM hematopoietic cells. The Fli1∆/∆ cells were severely compromised in terms of 
their expansion ability showing a 3-fold reduction in total CD45+ expansion and a 
further 8-fold reduction in KLS expansion (Figure 2.3D, E) pointing to defects not 
only in the differentiation of these progenitors but also their ability to self-renew and 
maintain their stem cell fate. A common theme that we observed with these KLS cells 
was the reduction in cKit as was seen in the AGM expansions. cKit levels were 
significantly reduced both in vivo in the expanded KLS population as well as in vitro 
post expansion showing two distinct populations of cKit high and cKit mid cells 
(Figure 2.3F, G). These results demonstrated Fli1∆/∆ mice are functionally 
compromised in their ability to self-renew, expand and differentiate in an ex-vivo 
platform. This dysfunction is linked to the Fli1-cKit axis which appears to be essential 
to maintain homeostasis.  
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Figure 2.3 Fli1 deletion results in expansion of a dysfunctional stem cell pool that 
is unable to self-renew, expand and differentiate in an ex-vivo setting (A) BM 
cellularity of two femurs in transplanted mice comparing Fli1 f/f or Fli1f/f Cre (B) Total 
KLS numbers in two femurs comparing Fli1 f/f or Fli1f/f Cre (C) Schematic showing 
experimental plan for tamoxifen induction followed by in vitro expansion (D) 
Representative flow plots showing gating strategy to assess KLS expansion in vitro (E) 
Quantification of CD45 and KLS expansion between Control and KO cells (F) 
Histograms showing cKit levels in vivo in BM KLS as well as post expansion in vitro 
in expanded KLS fraction (G) Quantification of cKit mean fluorescent intensity in vivo 
and post expansion in the KLS population (Statistics * signifies p < 0.05, ** signifies p 
< 0.01, *** signifies p < 0.001) 
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Having observed significant expansion and self-renewal defects in the MPPs we decided 
to further investigate the functionality of the HSCs by performing secondary transplants 
in conjugation with competitor CD45.1 WBM to ensure survival and BM homeostasis 
long term (Figure 2.4A). The peripheral blood engraftment of the Fli1∆/∆ cells in the 
secondary recipients was significantly lower compared to control Fli1f/f and was 
unchanged for the duration of 16 weeks (Figure 2.4B). This extended to all three 
peripheral blood lineages – myeloid, B cell and T cells (Figure 2.4C) assessed at Week 
16 pointing to an inherent stem cell defect that was funneling down to all peripheral 
blood lineages. In this context, the presence of competitor ensured that peripheral blood 
counts between the two transplant cohorts were the same and hematopoietic 
homeostasis was maintained. After 16 weeks, the BM of the mice was analyzed for 
engraftment in the stem cell and lineage compartments. The lack of engraftment seen in 
the peripheral blood was carried over to the BM showing minimal engraftment across 
the board, in both multipotent progenitors and long-term HSCs (Figure 2.4E, F). The 
engraftment was least in the LT-SLAM compartment with Fli1∆/∆ cells minimally 
present (Figure 2.4E). The lineage contribution of the Fli1∆/∆ cells in the BM was also 
drastically lower but still slightly higher compared to the stem cell compartment (Figure 
2.4F).  Importantly, the BM cellularity was unchanged between two cohorts due to the 
presence of CD45.1 cells (Figure 2.4D). This data shows that despite the initial 
expansion of the stem cell compartment as a result of the peripheral blood failure, the 
functionality of the LT-HSCs is severely compromised in terms of lineage contribution 
as well as engraftability and that in the absence of Fli1 the contribution of HSCs to 
hematopoiesis is minimal.  
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Figure 2.4 Fli1 regulates stem cell function in a cell autonomous manner (A) Mouse 
schematic showing experimental plan for secondary transplant to assess cell 
autonomous role of Fli1 (B) Peripheral blood engraftment assessed post-transplant for 
16 weeks comparing Control and KO contribution (C) Lineage contribution of Control 
and KO cells to T cells (CD3+), B cells (B220+) and Myeloid cells (Gr1+CD11b+) in 
peripheral blood analyzed at Week 16 prior to BM analysis (D) BM cellularity from two 
femurs comparing Control and KO (E) Engraftment in the LT-SLAM 
(CD45.2+cKit+Lineage-Sca1+CD150+CD48-) fraction of the BM at 16 weeks (F) 
Quantification of total engrafted CD45.2+ cells in the BM in the Lineage-, KLS and LT-
SLAM compartment (Statistics * signifies p < 0.05, ** signifies p < 0.01, *** signifies 
p < 0.001) 
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2.2.4 Fli1 is required for hematopoietic reconstitution 
 
After assessing the dysfunctional engraftment capabilities of Fli1 deleted 
hematopoietic cells in a secondary transplant setting, we asked if Fli1 is required for 
hematopoietic reconstitution in primary recipients. Given the initial hematopoietic 
insult that triggered an expansion in the stem cell pool in the primary transplants it is 
important to assay the potential of unmanipulated stem cells in their ability to 
reconstitute hematopoiesis. To this end, we employed two transplant settings, first, the 
Sca1 depletion assay in which Fli1f/f Cre or Fli1f/f KLS were transplanted with a 
radiation recovery dose of Sca1 depleted CD45.1 BM into lethally irradiated CD45.1 
mice. Deletion in these mice was induced one-week post transplantation so as to 
ascertain the ability of Fli1∆/∆ HSCs to take over from the radiation recovery dose. 
There was a significant difference in survival between the Controls and the KO mice 
with the majority of KO mice dying within 3 weeks (Figure 2.5A) of transplantation 
implying that Fli1∆/∆ HSCs are unable to sustain complete hematopoietic 
reconstitution. 
 
In the second setting, we assayed the possible lineage contribution of the Fli1 
deleted HSC. We transplanted Fli1f/f Cre or Fli1f/f KLS into lethally irradiated CD45.1 
mice with CD45.1 whole bone marrow so as to ensure survival of the transplanted 
mice (Figure 2.5B). The peripheral blood engraftment in this scenario was comparable 
to the secondary transplant (Figure 2.4B) and significantly lower than the control over 
the 16 weeks post-transplant (Figure 2.5D). The deleted Fli1 cells were significantly 
impaired in reconstituting all three lineages in peripheral blood – Myeloid, B and T 
cell (Figure 2.5C) once again, confirming that the differentiation of the Fli1∆/∆ HSCs 
is defective. The engraftment in the bone marrow was also significantly impaired  
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Figure 2.5 Fli1 is required for hematopoietic reconstitution (A) Sca1 depletion curve 
showing survival between Control and KO mice post-transplant (B) Mouse schematic 
showing experimental plan to assess hematopoietic reconstitution in primary recipients 
(C) Lineage contribution of Control and KO cells to T cells (CD3+), B cells (B220+) 
and Myeloid cells (Gr1+CD11b+) in peripheral blood analyzed at Week 16 prior to BM 
analysis (D)Peripheral blood engraftment assessed post-transplant for 16 weeks 
comparing Control and KO contribution (E) BM cellularity for two femurs at Week 18 
(F) Quantification of % total engrafted CD45.2+ cells in the BM in the Lineage-, KLS 
and LT-SLAM compartment  (Statistics * signifies p < 0.05, ** signifies p < 0.01, *** 
signifies p < 0.001) 
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Figure 2.6 Fli1 deletion results in reduction of peripheral blood contribution 
across all lineages (A) Mouse schematic showing experimental plan to assess effect 
of Fli1 deletion under homeostatic conditions (B) Peripheral blood engraftment 
assessed post-transplant for 24 weeks comparing Control and KO contribution. 
Lineage contribution of Control and KO cells to (C) Myeloid cells (Gr1+CD11b+), (D) 
B cells (B220+) and (E) T cells (CD3+) in peripheral blood analyzed for 24 weeks 
post-transplant (Statistics * signifies p < 0.05, ** signifies p < 0.01, *** signifies p < 
0.001) 
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when assessed at 18 weeks post-transplant (Figure 2.5F) affecting the Lineageneg, 
KLS and LT-SLAM compartments of the BM. The BM cellularity was not affected as 
were the peripheral blood counts ensuring that these measurements were made under 
homeostatic conditions post radiation (Figure 2.5E). The functional deficit extended 
from the HSC compartment all the way to the peripheral blood lineages demonstrating 
that Fli1 is essential for hematopoietic reconstitution and affects functionality of the 
LT-HSC in terms of self-renewal, expansion as well as differentiation during 
reconstitution. 
 
2.2.5 Fli1 is required for stem cell functionality during homeostasis 
 
Having confirmed the role of Fli1 during reconstitution in both a primary and 
secondary transplant setting, we next asked if Fli1 plays a similar role in the HSC 
compartment during homeostasis. In order to assess that we designed a transplant 
setting where the peripheral blood homeostasis is unaffected by deletion. Given the 
WBM transplant setting was lethal to the animals (Figure 2.2D) we transplanted 
competitor CD45.1 BM along with Fli1f/f Cre or Fli1f/f BM in equal ratios so as to 
have equal lineage contribution from the CD45.1 and the experimental cohort of cells. 
After allowing the transplanted mice to recover for 16 weeks, the deletion was induced 
with tamoxifen (Figure 2.6A). Post deletion the mice were monitored for 24 weeks to 
assess peripheral blood lineage contribution from the Fli1∆/∆ or Fli1f/f cells. Every 
timepoint was also assessed for peripheral blood counts to ensure that the 
hematopoietic homeostasis of the animal was maintained.  
 
There was a gradual decrease in the peripheral blood contribution (Figure 
2.6B) of the Fli1∆/∆ cells to varying degrees depending on the peripheral blood 
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lineage. The myeloid fraction was the first affected with Fli1∆/∆ contribution dropping 
significantly by week 8 (Figure 2.6C). The B cell compartment (Figure 2.6D) was 
slower to respond to the effect of the deletion with the T cells (Figure 2.6E) the last 
affected. All three compartments did show a significant reduction in engraftment by 
week 24. Peripheral blood complete blood counts were normal and unchanged 
between the control and KO cohort throughout the 24 weeks demonstrating the 
maintenance of peripheral blood homeostasis. The BM of the mice were assayed after 
6 months of deletion (Figure 2.7A) and was consistent with the peripheral blood 
exhibiting significantly reduced or close to absent engraftment from the Fli1∆/∆ cells 
compared to the controls (Figure 2.7E). BM cellularity was found to be slightly lower 
in the Fli1∆/∆ mice compared to the controls (Figure 2.7C). The presence of Fli1∆/∆ 
was not detected in the stem cell compartment in the BM (Figure 2.7D, E) showing 
minimal engraftment in both KLS as well as LT-SLAM populations (Figure 2.7B). 
The majority of adult HSCs are more or less dormant throughout the life of an 
organism. To observe such a drastic depletion in the HSC pool on Fli1 deletion points 
to an active mechanism that controls HSC fate irrespective of its active functional state 
suggesting that Fli1 is not only essential for reconstitution but critical for the 
maintenance and self-renewal of HSCs during adulthood under homeostatic 
conditions. 
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Figure 2.7 Fli1 is required for maintenance of HSC homeostasis (A) Mouse 
Schematic showing experimental plan to assess the effect of Fli1 on HSC homeostasis 
(B) Representative flow plots showing gating strategy to assess KLS-SLAM 
engraftment in 24-week BM (C) BM cellularity of two femurs in transplanted mice 
comparing Control and KO (D) Quantification of total engrafted CD45.2+ cells in the 
BM in the KLS and LT-SLAM compartment  (Statistics * signifies p < 0.05, ** signifies 
p < 0.01, *** signifies p < 0.001) (E) Quantification of % total engrafted CD45.2+ cells 
in the BM in the Lineage-, KLS and LT-SLAM compartment  (Statistics * signifies p < 
0.05, ** signifies p < 0.01, *** signifies p < 0.001) 
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2.2.6 Fli1 is essential for Ckit and Mpl expression and occupies critical hematopoietic 
promoter and enhancer regions in the genome 
 
Having confirmed the functional role of Fli1 in both a developmental setting as 
well as during adult homeostasis, we performed transcriptional analysis on the KLS 
compartment of the Fli1∆/∆ in the whole BM transplant setting to better understand the 
underlying mechanistic changes resulting in this drastic dysfunctionality. Previous 
ChIP data has shown extensive Fli1 binding in critical hematopoietic loci of 
transcription factors, epigenetic modulators and signaling cascade proteins; however, 
Fli1 is not unique in its genomic occupancy (Beck et al., 2013; Gottgens, 2015; 
Tijssen et al., 2011; Wilson et al., 2016). It shares a large number of binding sites with 
other genes of the heptad; however, deletion of a majority of these genes (Runx1, Scl, 
Lyl1, Lmo2) does not result in significant HSC defects suggesting a degree of 
redundancy and overlap with other transcription factors. Using human CD34+ ChIP 
data (Beck et al., 2013) we compared the total binding sites for 4 genes, Fli1, Erg, 
Runx1 and Gata2, and found that Erg and Fli1 have the most binding sites amongst 
these genes in promoter regions however the bulk of both Fli1 and Erg binding is in 
enhancer elements (Figure 2.8A). Erg dwarfs the other genes in this category 
occupying 42837 sites in annotated enhancers in CD34+ cells however Fli1 has the 
second most binding sites in enhancer and promoter elements. Distribution of binding 
sites amongst transcriptional start sites, intronic regions and intergenic regions is 
comparable between the four genes (Figure 2.8B). 
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Figure 2.8 Genomic occupancy of Fli1 in human CD34+ cells and transcriptional 
profiling of Fli1∆/∆ cells (A) Venn diagram representing transcription factor binding 
for Fli1, Runx1, Gata2 and Erg at annotated Promoters and Enhancers (B) Distribution 
of transcription factor binding sites in annotated genomic regions – Transcription start 
sites (TSS), transcription termination site (TTS), 3’and 5’ untranslated regions, exons, 
introns and intergenic regions. (C) RNA expression of the hematopoietic heptad in 
Fli1∆/∆ KLS cells is not affected (D) Genes that are significantly changed in KO cells vs 
Control 
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Figure 2.9 Genomic occupancy in hematopoietic loci of interest – cKit, Mpl, Gata2. 
Human CD34+ ChIP data for genomic occupancy of H3K27Ac, H3K4Me1, Fli1, Erg, 
Runx1, Gata2 and IgG at hematopoietic loci of cKit, Mpl and Gata2. Red boxes 
highlight binding peaks in promoter and enhancer regions. 
 
 
 
 
54 
 
By analyzing histone marks – H3K4me1 and H3 K27Ac, we found enhancer 
elements that are conserved across species in the hematopoietic stem cell compartment 
pointing to a specific role for Fli1 in gene regulation for HSCs (Figure 2.9). We first 
assessed the RNA profile of the hematopoietic heptad in the Control vs KO KLS cells 
and found that expression of these genes was unchanged (Figure 2.8C). This was not 
surprising given the overlap in genomic occupancy for most of these essential 
transcriptional regulators. One enhancer element that corelated well with a reduction 
in transcript level was Mpl (Figure 2.8D, 2.9). Mpl or thrombopoietin receptor has 
been shown to be essential for maintaining HSC quiescence as well as preserving HSC 
homeostasis in the niche (Fleury et al., 2010; Qian et al., 2007; Yoshihara et al., 2007). 
Both TPO (Thrombopoietin) and Mpl loss of function results in significant 
thrombocytopenia in addition to affecting HSC homeostasis. This function has not 
been explored in a cell type specific manner. ETS factor, Erg has also been linked with 
Mpl regulation before however it appears Fli1 and Erg may have non-redundant roles 
in Mpl regulation. Another unique binding site for Fli1 is in the promoter of the cKit 
gene (Figure 2.8D, 2.9). cKit has been shown to be essential for HSC survival and 
self-renewal however the exact mechanism of cKit regulation in adults is not well 
understood especially in the context of the hematopoietic stem cell (Heissig et al., 
2002; Kimura et al., 2011; Thoren et al., 2008).  
 
Both cKit and Mpl work in conjunction to maintain HSC quiescence and self-
renewal. Modulation of cKit expression on a protein level was confirmed during 
development as well as in adult, pre and post expansion ex vivo (Figure 2.1E, F, 2.3F, 
G). The steady reduction in peripheral blood engraftment in the BM homeostasis 
setting lends itself to a mechanism revolving around the disruption of HSC 
quiescence. Given the role of both these factors in this, they are prime candidates to 
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partially rescue the exhaustion phenotype associated with Fli1 deletion. Taken 
together these results show that Fli1 is a key regulator of the genomic landscape of 
HSCs and does so through unique binding sites throughout the genome as well as 
through regulation of cofactor binding in key enhancer elements to regulate specific 
genomic expression patterns unique to the hematopoietic stem cell compartment. 
 
2.2.7 Fli1 is required for ex-vivo expansion of hematopoietic cells 
 
After gaining a better understanding of the underlying mechanisms controlled 
by Fli1 in maintaining HSC fate we attempted to rescue the stem cell dysfunctionality 
of the Fli1 deleted HSCs by specifically overexpressing the two genes of interest 
identified through the transcriptional analysis of the Fli1 deleted HSCs, Kit and Mpl. 
In order to achieve this, we utilized the robust ex-vivo expansion platform of E4 
HUVECs to expand mouse KLS (Butler et al., 2010; Seandel et al., 2008). The ex-
vivo expansion of KLS allows the unique opportunity to manipulate gene expression 
in an ex-vivo setting and assess its effect on stem cell survival, self-renewal and 
differentiation. This system functions similar to what would be expected of an HSC in 
a transplant setting where it reconstitutes the entire hematopoietic system of the 
mouse.  
 
We first analyzed if Fli1 deleted KLS are able to expand in this ex-vivo setting 
(Figure 2.10A). A 10-day expansion experiment showed significant differences in the 
potential of the Fli1 deleted hematopoietic cells to expand. Superficial phase contrast 
images reflected a large difference in expansion potential between the Fli1∆/∆ and 
Fli1f/f cells (Figure 2.10B). There was a drastic reduction specifically in the KLS 
compartment post expansion with both, overall CD45 expansion as well as KLS  
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Figure 2.10 Fli1 deletion results in significant expansion defects in vitro (A) 
Schematic showing experimental design for in vitro expansion with deletion induced by 
4-hydroxy tamoxifen (B) Phase pictures showing differences in expansion between 
Control and KO (C) Representative flow plots showing gating strategy for analysis of 
KLS expansion demonstrating absence of KLS population in KO expansion. 
Quantification of invitro expansion across two different conditions of cytokine addition 
(only SCF (50ng/ml) and SCF, Flt3 and TPO (50ng/ml)) in terms of total (D) CD45 
expansion, (E) total Lineage- expansion and (F) total KLS expansion (Statistics * 
signifies p < 0.05, ** signifies p < 0.01, *** signifies p < 0.001) 
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expansion significantly reduced (Figure 2.10 D, E, F). Given the two genes of interest, 
cKit and Mpl, we assessed if the cytokine profile has any effect on the expansion of 
the Fli1∆/∆.  
 
A large number of cytokine-receptor interactions play a critical role in 
regulating the balance between HSC homeostasis vs expansion and differentiation. 
The vascular niche does provide a lot of essential cues for HSC maintenance and 
expansion however exogenous cytokines can be used to further improve expansion in 
the invitro setting(Butler et al., 2012; Butler et al., 2010). To this end we used 
exogenous thrombopoietin (TPO) and fms like tyrosine kinase 3 ligand (Flt3). Given 
the reduction in Mpl expression we hypothesized that the addition of TPO might 
modulate the kinetics of Mpl activation and rescue the Mpl axis induced defects in 
addition to the SCF-cKit defects. We found that the addition of TPO and Flt3 
significantly improved the self-renewal and expansion profile of the KO cells (Figure 
2.10 D, E, F) hinting at the kinetics of cytokine-receptor binding playing a key role in 
the deletion defect. Having attempted to improve expansion by the addition of 
cytokines, we sought to test the effects of removal of cytokines to gauge if Control and 
KO expansion is comparable without activating cKit and Mpl via their ligands, SCF 
and TPO (Figure 2.11C). There was no significant difference between total CD45+, 
Lineage- and KLS expansion in the absence (Figure 2.11D) of exogenous cytokines 
demonstrating that the SCF-cKit and TPO-Mpl axes are critical regulators of 
expansion and self-renewal in the in vitro expansion system.  
 
Given the recent findings implicating the role of megakaryocytes in HSC 
(Bruns et al., 2014) maintenance we modified the in vitro system to factor in the 
absence of megakaryocytes in the Fli1∆/∆ expansions by adding CD45.1 competitor  
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Figure 2.11 In vitro expansion in the presence of a competitor or absence of SCF 
does not affect Fli1∆/∆ expansion (A) Schematic showing experimental design for in 
vitro expansion with the addition of competitor (B) Quantification of invitro expansion 
in terms of total CD45 expansion, total Lineage- expansion and total KLS expansion 
(C) Schematic showing experimental design for in vitro expansion without exogenous 
SCF addition (D) Quantification of invitro expansion in terms of total CD45 expansion, 
total Lineage- expansion and total KLS expansion (Statistics * signifies p < 0.05, ** 
signifies p < 0.01, *** signifies p < 0.001) 
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KLS to both Control and KO expansions (Figure 2.11A). Fli1∆/∆ cells have deficient 
differentiation and the presence of CD45.1 cells would ensure that any supporting 
differentiated hematopoietic cell is present in the expansion for both Control and KO. 
Addition of CD45.1 KLS cells to the Control/KO KLS in vitro did not rescue the 
expansion deficit of the Fli1 deleted cells (Figure 2.11B) validating that 
megakaryocyte signaling is not involved in the expansion defect of the KO cells. 
 
Having established the baseline with respect to cytokine combinations as well 
as addition of exogenous competitor KLS, we moved to overexpressing two genes of 
interest, cKit and Mpl, in the KLS cells using lentiviral constructs so as to rescue the 
expansion defect of the Fli1 deleted stem cells. An important fact to keep in mind is 
that HSC homeostasis entails a diverse repertoire of functions – self-renewal, 
expansion and differentiation. Mpl and cKit target a small part of these various HSC 
functions. The main target of this rescue would be to maintain the number and 
percentage of KLS cells in vitro when compared to the control factoring in the starting 
population of cells. We found that lentiviral overexpression of Mpl resulted in a 
significant increase in the expansion potential of the Fli1 deleted KLS and was able to 
override the expansion defect in the stem cell compartment only (Figure 2.12B, C). 
This translated to a slight increase in total CD45 expansion while giving a significant 
increase in the KLS fraction which was earlier specifically depleted (Figure 2.12B). 
Kit overexpression was able to prevent the reduction in KLS numbers while 
maintaining surface marker expression of the stem cell compartment (Figure 2.10C) 
which is lost in the Fli1 deleted cells; however, expansion was not significantly 
affected by its overexpression. This is not completely unexpected as Kit has been 
linked with HSC self-renewal and survival more so than expansion and differentiation. 
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Taken together these results show that Fli1 regulates HSC survival, self-
renewal and expansion by regulating the expression of Kit and Mpl and through their 
interaction with SCF and TPO. These rescue experiments provide a mechanistic 
insight into some of the various pathways regulated by Fli1 in maintaining 
hematopoietic stem cell homeostasis in the context of stem cell fate. 
 
In conclusion, we demonstrate that Fli1 is essential for definitive 
hematopoiesis during development. It carries over this function to adult mice 
where it is required for hematopoietic homeostasis and is critical in maintaining 
hematopoietic stem cell function in the context of homeostasis as well as 
reconstitution. Fli1 regulates hematopoietic survival, self-renewal and expansion 
via two major signaling proteins – cKit and Mpl. Future studies should focus on 
deciphering the clinical relevance of Fli1 as a target in the context of leukemia 
and bone marrow transplantation. 
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Figure 2.12 Rescue of Fli1 deletion expansion defect by overexpression of cKit and 
Mpl (A) Schematic showing experimental design for in vitro expansion (B) 
Quantification of invitro expansion in terms of total CD45 expansion and total Lineage- 
expansion (C) Quantification of invitro expansion in terms of total KLS expansion and 
%KLS post-expansion  
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CHAPTER 3: FLI1 AND ERG MAINTAIN A CORE VASCULAR PROGRAM 
ESSENTIAL FOR ADULT VASCULAR CELL FATE 
 
3.1 INTRODUCTION 
 
The ETS family of factors has been implicated in regulating a wide array of 
cellular processes in vascular endothelial cell development as well as angiogenesis. 
While the precise hierarchy of transcription factors that regulate endothelial cell fate 
has been defined, whether vascular cell fate in adults is dependent on constitutive 
command of specific ETS transcription factors remain unknown. Our group has 
previously demonstrated that direct differentiation of mid-gestation human and mouse 
non-vascular cells to endothelial cells can be achieved through the expression of three 
of these factors – Etv2, Fli1 and Erg (Ginsberg et al., 2012; Schachterle et al., 2017). 
This prompted us to hypothesize that there may exist a core transcription factor(s) that 
are responsible for maintaining the endothelial cell repertoire and fate during 
adulthood. As is the case with hematopoiesis, there is a significant difference in the 
requirement of a factor during development as compared to adulthood (Chen et al., 
2009). This holds true for the vasculature as well. Etv2 expression is restricted to a 
short window during development (Kataoka et al., 2011; Meadows et al., 2011) 
however it is not expressed in endothelial cells after mid-gestation or postnatally. A 
wide array of factors that are implicated during vasculogenesis and angiogenesis in 
development are not necessarily essential to maintain vascular homeostasis and 
endothelial cell fate during adulthood (Hooper et al., 2009; Shalaby et al., 1995). The 
ability to identify crucial transcription factors that regulate vascular cell fate would 
offer significant insight into the key pathways required for maintaining ECs in vitro 
and developing tractable platforms to sustain faithful ECs cell fate in the context of 
vascular disease and cancer. 
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Fli1 has been shown to play a role in regulating vascular leakiness during 
development and to a lesser degree in adult mice (Asano et al., 2010; Hart et al., 2000) 
and we sought to further explore the role of Fli1 in the context of vascular 
heterogeneity as well as homeostasis. Erg, a closely related ETS family transcription 
factor has been shown to play a role both in hematopoiesis and endothelial cell 
function in HUVECs as well as mice (Birdsey et al., 2008; Birdsey et al., 2012; 
Birdsey et al., 2015; Dryden et al., 2012; Dufton et al., 2017; Shah et al., 2017). The 
close homology and overlapping binding sites (Beck et al., 2013; Tijssen et al., 
2011; Wilson et al., 2010) in other cell types led us to hypothesize that there may 
exist a redundancy in terms of the function of these two factors in maintaining 
endothelial cell fate and homeostasis.  
 
Here we show that Fli1 by itself, is not essential to maintain endothelial cell 
fate in adult mice and regulate vascular heterogeneity in the context of certain vascular 
beds. Erg does play an active role in angiogenesis during post-natal development 
(Birdsey et al., 2015) however in adults it is characterized by mild fibrotic phenotypes 
(Dufton et al., 2017). Notably, we demonstrate that acting together, Fli1 and Erg are 
essential in the maintenance of a core vascular program required for homeostasis in 
adult mice. Deletion of both these factors results in lethality by Day 12 due to 
hemorrhage and the formation of thrombi in the liver while in vitro, importantly, there 
is a complete loss in EC identity on the basis of essential marker expression such as 
VE-Cadherin, CD31 and VEGFR2. 
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3.2 RESULTS 
 
3.2.1 Fli1 is not essential for endothelial homeostasis during development in the post-
natal retina  
 
 
Fli1 is expressed in every vascular bed in adult mice and given the early 
vascular implications of Fli1 knockout mice with vascular leakiness leading to 
embryonic lethality (Hart et al., 2000; Spyropoulos et al., 2000), we hypothesized that 
it may be one of the key factors involved in maintaining vascular identity. In order to 
test this hypothesis, we crossed Fli1f/f mice (Starck et al., 2010) with two different Cre 
lines, the inducible VE-Cadherin (Cdh5) CreERT2 (Pitulescu et al., 2010)and the 
developmental Cdh5-cre-1 (Zovein et al., 2008). The late developmental Cdh5-cre-1 
(Zovein et al., 2008) induces deletion a day later than the developmental Cdh5-cre due 
to which hematopoietic deletion and the extent of endothelial deletion is much lower. 
This is as a result of different sized promoter elements of Cdh5 being used to induce 
Cre expression in the mice. Cdh5-cre-1 did not phenocopy the embryonic or post-natal 
lethality seen with the global deletion or with the developmental Cdh5-cre (Chen et 
al., 2009; Speck and Iruela-Arispe, 2009) that targets the AGM. Mice were born in 
expected mendelian ratios (Figure 3.1B). Whole mount imaging of E11.5 embryos did 
not yield any significant changes in endothelial architecture between the Control and 
Fli1 knockout mice (Figure 3.1A). The focus of our study was to evaluate the effect of 
Fli1 in adult vascular homeostasis. To this end, we began to explore the role of Fli1 in 
angiogenesis in post-natal retina. The retina offers a unique system to track vascular 
growth and regression in a 2D field (Pitulescu et al., 2010). We used both inducible 
and developmental cre mice to evaluate angiogenic defects in the retina however there  
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Figure 3.1 Fli1 is not essential for endothelial cell homeostasis during development 
and in the post-natal retina. (A) Whole mount CD31 staining of endothelial cells of 
Fli1f/f Cdh5-cre E11.5 embryos. (B) Observed and Expected numbers for genotypes 
from Fli1f/f Cdh5-cre breeders showing number of adult mice > 4wks (C) Representative 
images of isolated P7 retinas of Control and KO pups 
 
were no significant differences between the Fli1f/f and Fli1∆EC/∆EC in terms of density, 
patterning and overall vascular architecture (Figure 3.1C). Thus, Fli1 may not be 
involved with the establishment of vascular structures during development or post-
natally. 
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Figure 3.2 Fli1 does not affect EC architecture and is not required for recovery 
from Hind Limb Ischemia. (A) Representative images of lung vasculature of Control 
Fli1f/f compared to Fli1f/f Cdh5 cre. Stains are shown for intravital labelling of Isolectin 
and VE-Cadherin. Nuclei were labeled with DAPI. (B) Representative images showing 
blood flow recovery in HLI model between Control and KO over 12 days. (C) 
Quantification of the fold recovery of ligated leg over control leg in four experimental 
cohorts – Control, KO, Control + EC, KO + EC 
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3.2.2 Fli1 deletion does not impair vascular architecture in adult mice and does not 
regulate the angiocrine repertoire of endothelial cells in the context of bone marrow 
recovery and hind limb ischemia 
 
After assessing the role of Fli1 during development and in the post-natal retina, 
we questioned if Fli1 might play a role in regulating the angiogenic and angiocrine 
profile of endothelial cells in specific organ beds. The heterogeneity of vascular beds 
has been proposed to be critical in regulating organ development, regeneration and  
homeostasis (Benedicto et al., 2017; Ding et al., 2010; Ding et al., 2011; Nolan et al., 
2013; Rafii et al., 2016; Wertheimer et al., 2018) and so we investigated if Fli1 may  
play a role in the context of specific organ heterogeneity. We initially assayed the 
endothelial cell architecture and density in different vascular beds using intravital 
labelling using fluorescently conjugated VE-Cadherin antibody but found that there 
was no significant difference between the Fli1f/f and Fli1∆EC/∆EC mice (Figure 3.2A). 
This was evaluated across several different deletion conditions ranging from 
developmental deletion to post-natal deletion at P2-P4 as well as adult deletion post 
Week 8.  
 
Having assessed the role of Fli1 in regulating the angiogenic repertoire of 
endothelial cells during homeostasis we questioned if Fli1 may play a role in 
maintaining specific angiocrine functions of endothelial cells in the context of 
recovery during physiological stress. Hematopoietic recovery post sublethal radiation 
is a well-established system where the role of endothelial cells in specific contexts has 
been explored (Butler et al., 2010; Kobayashi et al., 2010; Poulos et al., 2015). We 
first assessed if there were any differences in basal counts of the mice with respect to 
peripheral blood during homeostasis and found there was no difference between the  
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Figure 3.3 Endothelial Fli1 is not required for hematopoietic recovery from 
sublethal radiation. (A) Schematic for experimental plan to assess peripheral blood 
recovery from sublethal radiation, peripheral blood counts for WBC (x103 cells/µl), 
RBC (x106 cells/µl), Platelets (x103 cells/µl), Hemoglobin (g/dL) and Hematocrit (%) 
assayed at Day 7, 14, 21 and 28 (n=6 mice). (B) Bone marrow cellularity measured per 
femur at Day 28 post radiation. (C) Lineage negative cell counts per femur post lineage 
depletion using Miltenyi lineage depletion kit. (D) KLS (cKit+LineagenegSca1+) cells 
measured per femur in the lineage negative fraction. (E) HSC LT-SLAM (KLS 
CD150+CD48-) numbers measured per femur in the lineage negative fraction. (B-D) 
BM Analysis was performed on n=3 mice per cohort and all measurements were found 
to be not significant 
 
Fli1f/f (n=6) and Fli1∆EC/∆EC (n=7) mice. We next proceeded with determining the 
response of the mice in the context of radiation damage. To this end, we irradiated the 
mice with sublethal 650 rads and assessed their recovery in terms of the complete 
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peripheral blood counts as well as differential WBC counts and distribution (Figure 
3.3A). The recovery profile of the peripheral blood for the Controls compared to the 
knockouts was unchanged showing that Fli1 may not play a significant role in 
maintaining the angiocrine profile of bone marrow endothelial cells during 
homeostasis or recovery. Despite the absence of any difference in recovery, we 
studied if the bone marrrow niche was affected in terms of its ability to sustain stem 
cell homeostasis. After harvesting bone marrow at Week 4 post radiation, we found 
that bone marrow cellularity was unchanged by Fli1 deletion (Figure 3.3B). This 
extended to every subsequent lineage restricted compartment with the lineage negative 
cellularity unaffected between control and KO mice (Figure 3.3C). The stem cell 
compartment was not significantly different with KLS numbers as well as LT-SLAM 
(KLS CD150+CD48-) hematopoietic stem cell numbers (Figure 3.3D, E) manifesting 
no difference between the experimental cohorts. 
 
Having evaluated the bone marrow, we hypothesized that a more rigorous 
vascular insult might better assess the importance of Fli1 in the context of recovery. 
The hind limb ischemia model has been shown to be an ideal system to assess 
angiogenic as well as angiocrine function during revascularization and has proven to 
be a relevant model to quantify endothelial cell engraftment (Jin et al., 2006; 
Schachterle et al., 2017). To test the effect of Fli1 in hind limb ischemia model, we 
performed excision of the femoral artery followed by injection of 5x105 Akt 
transduced endothelial cells (Schachterle et al., 2017) to identify any advantage of 
exogenously supplied endothelial cells in the Fli1∆EC/∆EC. We found that the four 
cohorts of Control, KO, Control transplanted and KO transplanted had comparable 
effect in revascularization (Figure 3.2B, C) from the hind limb ischemia prompting us  
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Figure 3.4 Fli1 and Erg maintain endothelial integrity during homeostasis. (A) 
Mouse schematic showing breeding strategy to obtain adult mice and tamoxifen 
injection schedule for adult mice. (B) Survival curve for post first injection of tamoxifen 
for four cohorts – Fli1f/f Ergf/f cre (n=6), Fli1f/f Ergf/f (n=4), Fli1f/+ Ergf/f cre (n=2), 
Fli1f/+ Ergf/f (n=2). (C) Peripheral blood counts comparing WBC (x103 cells/µl) and 
Platelets (x103 cells/µl) from Fli1f/f Ergf/f cre and Fli1f/f Ergf/f mice. (D) Serum levels 
of ALP (U/L), ALT (U/L), AST (U/L) and LDH (U/L) between Control and DKO mice. 
(E) H&E histology sections of the liver comparing Control with DKO mice exhibiting 
thrombus formation in major vessels. 
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to conclude that Fli1 by itself, is not responsible for maintaining the angiogenic and 
angiocrine profile of endothelial cells in the different vascular beds. 
 
3.2.3 Fli1 and Erg maintain endothelial integrity during homeostasis 
 
Having assessed the role of Fli1 in vascular homeostasis and in the context of 
ischemic revascularization, we hypothesized that Erg may be the more crucial factor 
for endothelial cell fate. Erg has been shown to regulate several key vascular markers 
in human umbilical vein endothelial cells (Birdsey et al., 2008; Birdsey et al., 2012; 
Dryden et al., 2012; Sperone et al., 2011; Starke et al., 2011) in addition to being 
essential for endothelial cell fate stability during development. Endothelial specific 
deletion of Erg results in defects in vascular permeability in addition to angiogenic 
defects in the developing embryo (Birdsey et al., 2015; Dufton et al., 2017; Shah et al., 
2017). However, in the context of adult homeostasis, Erg shared a similar fate to Fli1 
in exhibiting a minimal functional role. We hypothesized that Fli1 and Erg may 
have redundant functions in maintaining endothelial homeostasis in adult mice 
due to which their single deletions do not show significant impact with respect to 
endothelial stability. In order to test this hypothesis, we acquired Ergf/f (Birdsey et 
al., 2015) mice from the Randi lab and crossed them to our Fli1f/f Cdh5-CreERT2 mice 
(Figure 3.4A).   
 
Tamoxifen-mediated cre deletion was induced in adult mice that were at least 
12 weeks old. The endothelial cell specific deletion of Fli1 and Erg was lethal and 
resulted in death between Day 10 and Day 12 post tamoxifen injection (Figure 3.4B). 
The control mice that were Ergf/+ Fli1f/f Cdh5-CreERT2 were unaffected by the deletion 
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pointing to a very specific dosage requirement with respect to Erg and Fli1 deletion. 
Upon further inspection, mice at Day 10-12 post tamoxifen had significant hyperemia 
in the liver pointing to possible vascular leakiness. The peripheral blood counts of 
these mice were tested to assess for any hematopoietic dysfunction. There was a 
significant increase in WBC counts in peripheral blood with a significant decrease in 
platelet numbers (Figure 3.4C) while RBC, Hematocrit and hemoglobin counts were 
unaffected. One of the critical functions of endothelial cells is to maintain homeostasis 
in the coagulation cascade. Damaged endothelium can trigger platelet activation 
through two broad mechanisms – the first being in a cell autonomous manner where 
the ECs express factors that are prothrombogenic and activate complement system as 
well as activating platelets to initiate coagulation. The other is through vascular 
leakiness or detachment which results in the exposure of ECM. Deposited 
extracellular matrix has prothrombogenic factors such as different collagens that can 
activate clotting mechanisms and triggering the formation of thrombi. We hypothesize 
that global dysregulation of endothelial cell homeostasis would result in platelet 
activation that the body cannot cope with in terms of maintaining platelet numbers 
adequate to sustain homeostasis. This was confirmed by histological analysis which 
revealed the formation of large thrombi in both large vessels and sinusoids with 
significant infiltration of hematopoietic cells which explains the increase in WBC 
counts in the peripheral blood (Figure 3.4E). In order to ascertain the cause of death, 
we assayed serum from the mice. Blood was drawn by retroorbital bleed and allowed 
to coagulate at room temperature for an hour. Serum was obtained by pelleting cells 
post coagulation and collecting supernatant. The levels of ALT (alanine 
aminotransferase), AST (aspartate aminotransferase) and LDH (lactate 
dehydrogenase) in serum were significantly elevated (Figure 3.4D) with respect to 
control mice pointing to serious liver damage.  
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Taken together, these results strongly suggest that Fli1 and Erg expression is 
critical for vascular homeostasis and survival. More importantly, their deletion affects 
platelet homeostasis and the coagulation cascade that is maintained by the vasculature. 
The liver appears to be the most affected in terms of vascular dysfunction. 
Nonetheless, it is plausible that if the mice could survive the initial pro-thrombotic 
insult other organs could also succumb to vascular thrombosis 
 
3.2.4 Absence of Fli1 and Erg results in significant disruption of endothelial cell 
architecture and loss of vascular signature 
 
After evaluating the systemic effect of endothelial deletion of Fli1 and Erg, we 
inquired as to what the impact of Fli1-Erg deletion was on each vascular bed. Our 
group has shown previously that every vascular bed has a unique signature that 
enables it to maintain the homeostasis in that organ while at the same time being 
primed to react to any kind of injury to the specific microenvironment (Nolan et al., 
2013). A retroorbital injection of preconjugated VE-Cadherin enables us to intravitally  
label the endothelium for flow analysis as well as immunofluorescence. Flow analysis 
revealed a significant reduction in terms of the percentage of ECs in the liver as well as 
a significant increase in the hematopoietic infiltration through %CD45 cells (Figure 
3.5A, B), corroborating the observations of the histological sections of the liver 
manifesting hematopoietic infiltration in the vicinity of the large vessels in addition to 
the thrombus formation. Additionally, the regions of the liver most affected were the 
sinusoids with the VE-Cadherin expression in the large vessels, the least affected. The 
reduction in VE-Cadherin staining was observed in the lung and the spleen as well with 
the endothelial cell architecture in the spleen the most severely affected (Figure  
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Figure 3.5 Fli1 and Erg regulate VE-Cadherin expression in endothelial cells and 
are essential for maintenance of endothelial architecture in different vascular beds. 
(A) Representative flow plots showing staining schema for analysis of endothelial cell 
populations in harvested livers from control and double KO mice. After initial CD45 
exclusion, endothelial cells were identified by the expression of CD31 and VE-
Cadherin. Lymphatic contamination was eliminated based on Podoplanin staining. 
Histogram shows distribution of VE-Cadherin MFI in the population of ECs. (B) 
Quantification of %EC as a fraction of Live singlets CD45- cells, %CD45 as a fraction 
of total Live singlets, Mean Fluorescent Intensity of VE-Cadherin normalized to 
Control. (C) Representative IF images of different vascular beds – Liver, Spleen, Lung 
and Kidney between Control and KO showing endothelial architecture identified by VE-
Cadherin staining from intravital labeling of ECs by VE-Cadherin. 
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3.5C, 3.6). There was a direct correlation with the type of vascular bed in terms of 
their capillary structure (Cleaver and Melton, 2003) and the degree of vascular 
disruption with fenestrated capillaries in kidney glomeruli showing significant leakage 
of the antibody (Figure 3.6). Similarly, the spleen lost the differentiation zone between 
the red and white pulp. 
 
Given the significant drop in platelet counts, we expected the bone marrow 
homeostasis to be disturbed. A drop in peripheral blood counts would normally trigger 
an expansion of the KLS compartment of the bone marrow as seen in the case of Fli1 
deletion in the hematopoietic compartment in Chapter 2 however what we observed 
was a significant decrease in both the KLS and LT-SLAM (Figure 3.7A) HSCs (Kiel 
et al., 2005) compartment in the double knock out mice compared to the controls 
(Figure 3.7C). A possible reason for the reduction in the stem cell compartment might 
have been a broader effect in the bone marrow as a result of disruption of the 
vasculature. This would have been reflected in overall bone marrow cellularity as well 
as a drop in the lineage negative fraction of the bone marrow however these counts 
were not affected by Fli1 Erg deletion (Figure 3.7B). This points to a disruption in the 
bone marrow niche specifically regulating hematopoietic stem cell homeostasis 
resulting in decrease in the total number of hematopoietic stem cells in the bone 
marrow. In order to further evaluate the mechanism behind the hematopoietic stem 
cell disruption it would be necessary to separate the effect of angiocrine regulation of 
hematopoietic stem cells and architectural endothelial cell support provided. The 
invitro platform for hematopoietic expansion will serve as an ideal model to elucidate 
this mechanism and will be the focus of future studies. 
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Figure 3.6 Fli1 and Erg are essential for endothelial architecture and control 
vascular leakiness. Representative images of Liver, Spleen and Kidney emphasizing 
the disruption of endothelial architecture at higher magnification along with increased 
antibody leakiness in the kidney glomeruli in the Double KO compared to the Control.  
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Figure 3.7 Endothelial Fli1 and Erg maintain Bone Marrow HSC homeostasis. (A) 
Representative flow plots showing analysis schematic to assay BM HSC LT-SLAM 
populations. Gated on Live singlets that were CD45+. (B) Bone marrow cellularity and 
Lineage negative cellularity measured per two femurs comparing Control and KO mice. 
Lineage depletion was carried out using Miltenyi lineage depletion kit (C) KLS 
(cKit+LineagenegSca1+) cells measured per two femurs in the lineage negative fraction. 
HSC LT-SLAM (KLS CD150+CD48-) numbers measured per two femurs in the lineage 
negative fraction. (Statistical significance, * for p value < 0.05, *** for p value < 0.001) 
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Therefore, Fli1 and Erg are not only involved in maintaining endothelial cell 
homeostasis and integrity but are also important to enforce the expression of 
endothelial cell markers essential for regulating vascular structures in addition to the 
angiocrine profile of endothelial cells critical for bone marrow HSC homeostasis. 
 
3.2.5 In vitro analysis of Fli1-Erg deletion in endothelial cells 
 
One of the caveats of a drastic homeostatic disruption that leads to early 
lethality is that we cannot assess the full extent of phenotypic and functional impact on 
the endothelial cell population. A minor loss in junctional integrity can lead to 
immediate lethality and we hypothesized that since this is rampant on a global scale in 
the mice we are unable to assess whether there is a loss in endothelial cell fate. In 
order to further analyze the fate of the endothelial cells we switched to an in vitro 
system so as to be able to identify changes in the cells over a period of time. Having 
seen the most drastic effect of Fli1-Erg deletion in the liver we decided to use liver 
ECs as our primary vascular bed for analysis in vitro. ECs were isolated by CD31 
conjugated beads and sorted for purity so as to ensure 100% CD31+VE-
Cadherin+CD45- authentic endothelial cells as the starting population, before inducing 
deletion (Figure 3.8A). In order to account for the effects of hydroxy tamoxifen, both 
Control and KO samples were assessed with and without hydroxy tamoxifen.  
 
After deletion, the knockout endothelial cells began to lose their prototypical  
morphology and acquired a more mesenchymal appearance by Day 4 (Figure 3.8D). 
Additionally, as early as Day 4 post deletion there was a reduction in the levels of CD31 
and VE-Cadherin when observed by live staining under confocal microscopy.  
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Figure 3.8 In vitro analysis reveals Fli1 and Erg are essential in maintaining 
endothelial morphology and endothelial cell fate. (A) Schematic detailing 
experimental plan for EC isolation for in vitro culture using CD31 conjugated magnetic 
beads followed by re-purification to ensure pure endothelial cell starting population 
before inducing deletion (B) Representative flow plots showing gating schema for 
isolation of endothelial cells. Histograms showing mean fluorescent intensity for two 
critical endothelial cell markers VE-Cadherin and CD31 (C) Quantification of 
endothelial cell purity at Day 7 post deletion based on CD31, VE-Cadherin expression 
and MFI for CD31 and VE-Cadherin (D) Representative images showing live staining 
for VE-Cadherin (Red) and CD31 (Green) along with Phase to show morphological 
changes in the endothelial cells at Day 7 post deletion of Fli1 and Erg. 
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The cells were analyzed at Day 7 post deletion to assess morphology, surface marker 
expression of CD31 and VE-Cadherin by microscopy as well as flow. Live confocal 
staining revealed a significant disruption in CD31 and VE-Cadherin staining in the 
majority of endothelial cells in the deleted primary liver (Figure 3.8D). The majority 
of cells had lost the junctional staining for VE-Cadherin and CD31, while a few 
pockets maintained single marker expression. Junctional staining was unaffected in the 
other three controls – Control Fli1f/f Ergf/f, Control with 4-OHT and DKO Fli1f/f Ergf/f 
Cre. Flow analysis confirmed the loss of endothelial cell markers in vitro showing a 
drastic reduction in the expression of CD31 as well as VE-Cadherin (Figure 3.8B). 
Having confirmed the surface marker expression of some essential endothelial cell 
core genes, we sought to confirm the change in the transcriptional profile of these 
deleted cells. RNA was collected at Day 7 and compared to Control treated with 4-
OHT after normalizing gene expression to β-Actin expression. RNA profiling 
confirmed the deletion efficiency for both Fli1 and Erg and was consistent with the 
observed reduction of CD31 and VE-Cadherin at protein level (Figure 3.9). 
Additionally, other core endothelial genes – VEGFR2, cKit, Tie2 and Sox17 were 
significantly reduced. One of the hallmark genes of mesenchymal transition, α-SMA 
was 6.5-fold upregulated. Collectively, these data indicate that Fli1 and Erg are 
essential for sustaining endothelial cell fate and preventing transitioning to non-
vascular cell fate. 
 
It is not surprising that the degree of reduction in marker expression could not 
be seen in vivo since the mice would not be able to survive such a global loss in 
endothelial marker expression. The in vitro system gives us a robust platform to 
decipher the molecular underpinnings governing this drastic fate loss in endothelial  
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Figure 3.9 Transcriptional analysis of Fli1 Erg deleted cells shows significant 
reduction in key endothelial genes along with an increase in mesenchymal 
markers. RNA levels of important endothelial genes analyzed by qPCR and normalized 
to β Actin levels. Relative gene levels were then normalized to expression in Control 
cells to calculate fold change in double KO cells 
 
cells. More detailed RNA and protein analysis would give an insight into what 
pathways could be used to rescue the disruption of endothelial homeostasis. 
 
3.2.6 Genomic occupancy and transcriptional profiling reveal an essential role of Fli1 
and Erg as master regulators of a core endothelial cell program 
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Having explored the phenotypic aspect of the Fli1-Erg deletion on survival, 
homeostasis and the vasculature we attempted to gain some insight into the underlying 
mechanisms regulating this drastic endothelial dysfunction. In order to achieve this, 
we took a two-pronged approach looking at genomic occupancy of Fli1 across 
different vascular beds using ChIP as well as analyzing changes at the RNA level in 
the endothelial cells in different vascular beds. 
 
We employed both the mouse and the human system to assess genomic 
occupancy of Fli1 and Erg in endothelial cells. HUVEC ChIP data was analyzed from 
available online datasets to compare binding profiles of the two ETS factors. Fli1 and 
Erg had very similar binding profiles in terms of distribution of binding sites. The total 
number of binding sites of Fli1 and Erg in HUVECs were 3695 and 3648 respectively 
with comparable distributions between transcriptional start sites, intron and intergenic 
binding (Figure 3.10A). Annotated gene promoter binding was higher in Erg with 
1664 genes compared to 1447 for Fli1 however only 827 of these genes had 
overlapping binding sites suggesting a distinct purview for each of these factors in the 
context of promoter occupancy (Figure 3.10B). Enhancers play an equally important 
role in regulating gene expression. By using p300 binding in conjunction with 
H3K27Ac histone marks to identify active enhancers we were able to compare 
enhancer binding between Fli1 and Erg. Overlapping binding for Fli1 and Erg in 
enhancers identified 399 peaks with single Fli1 occupancy at 187 peaks and single Erg 
occupancy at 132 (Figure 3.10C).  
 
After analyzing the human system, we used primary mouse liver endothelial 
cells that were sorted and pooled to perform a Fli1 ChIP. Fli1 occupancy was assessed  
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Figure 3.10 Genomic occupancy of Fli1 and Erg in HUVECs reveals similar 
genomic purviews. (A) Distribution of Fli1 and Erg binding sites in annotated genomic 
regions – Transcription start sites (TSS), transcription termination site (TTS), 3’and 5’ 
untranslated regions, exons, introns and intergenic regions. (B) Venn diagram 
representing Fli1 an Erg occupancy in promoter regions of genes and the number of 
overlapping gene promoter regions (C) Venn diagram detailing enhancer occupancy of 
Fli1 and Erg based on p300 and H3K27Ac peaks in HUVECs.  
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Figure 3.11 Genomic occupancy of Fli1 in essential endothelial genes. Fli1 
occupancy in primary mouse liver endothelial cells in endothelial gene loci of interest. 
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at critical genetic loci to corroborate the drastic endothelial transition that was seen in 
vitro and in vivo. Fli1 was found to occupy all critical genetic loci of endothelial genes 
with promoter occupancy in Cdh5 (VE-Cadherin), Kdr (VEGFR2), Pecam1 (CD31), 
Tek (Tie2), Dll4 and many more (Figure 3.11). Additionally, Fli1 was also found to 
occupy the promoter region in the PF4 (platelet factor IV) gene which is primarily 
expressed in megakaryocytes and platelets, hinting at a previously understudied 
repressive function for Fli1 in endothelial cells.  
 
The genomic purview of both these factors lends to their importance in 
regulating a core endothelial program essential for vascular homeostasis. Having 
observed the in vivo and in vitro consequences of Fli1-Erg deletion along with an 
understanding of the possible targets regulated by these two genes it was important to 
explore the transcriptional profile of these cells. RNA analysis would complement the 
genomic purview and unravel the underlying mechanisms governing EC fate loss. 
 
In order to analyze the RNA, we isolated endothelial cells from three different 
vascular beds – Lung, liver and heart at Day 9 post tamoxifen injection so as to 
circumvent the issue of platelet contamination as a result of the thrombi formation in 
the moribund mice. Samples were processed for bulk RNA as well as single cell 
analysis. The Day 9 samples showed a significant increase in various categories 
covering extracellular matrix organization, cell migration, integrin signaling, 
angiogenesis and cell adhesion (Figure 3.12A, 3.13). The main pathways affected 
were the HIF-1 signaling, TGF-β signaling, MAPK signaling with hematopoietic 
lineage genes being upregulated as well (Figure 3.12B). We hypothesize a two-step 
mechanism in the effect of Fli1-Erg deletion with the first stage being associated 
with an upregulation of a large number of genes that are regulated by these 
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Figure 3.12 Gene ontology and KEGG pathway analysis. (A) Gene ontology analysis 
of significantly upregulated and downregulated genes across all three vascular beds (B) 
KEGG pathway analysis of significantly upregulated and downregulated genes across 
all three vascular beds 
 
factors centered around ECM interactions and integrin signaling. This precedes 
the reduction in endothelial core factor reduction which together triggers an imbalance 
in the platelet activation pathway along with hematopoietic homeostasis and thrombus 
formation that causes lethality. 
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Figure 3.13 RNA Heatmaps reveal consistent changes across ECM receptor 
interactions (A), Angiogenesis (B), Response to Hypoxia (C) and Cell Adhesion (D) 
categories 
 
 
 
A B 
C D 
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Single cell RNA analysis of the liver endothelial cells was carried out to 
explore mosaic expression of genes that may lead to endothelial disruption. Two 
Control and KO livers were analyzed at Day 9 post first injection. An unbiased  
clustering of endothelial cells revealed 8 clusters in liver ECs (Figure 3.14A). The first 
5 clusters 0-4 segregated perfectly based on the sample with majority of Control ECs  
contributing to Cluster 0, 1 while the KOs clustered mainly in the group 2-4 (Figure 
3.14B, C, D). Clusters 5, 6 and 7 had a much lower cell count and were not 
differentially segregated between Control and KO samples (Figure 3.14C, D). The  
clear segregation of the Control and KO samples allows for an easy readout of 
differential gene expression using violin plots (Figure 3.15). Violin plots for specific 
endothelial genes revealed a significant reduction in the expression pattern in clusters 
2, 3, 4 while control clusters had an abundance of the EC specific genes (Figure 
3.15A). Some genes that showed clear segregation were Tek (Tie2), Jam2, Lyve1, 
Sox18, ROBO4 and Dll4 while other genes associated with a more mesenchymal fate 
or loss in endothelial fate were found to be upregulated in the KO clusters. These were 
Col4a2, Tgfbr2, Ltbp4 and Itgb3.  
 
Henceforth, Fli1 and Erg are actively enforcing a majority of critical 
endothelial cell functions. Their combined genomic purview encompasses a core 
transcriptional program that ensures endothelial cell fate and homeostasis not just in 
the context of endothelial cells but the supporting cells that are dependent on 
endothelial angiocrine signals to maintain homeostasis. Having assessed the genomic 
locations of these ETS factors and combining them with transcriptional profiling of 
ECs in bulk as well as at single cell resolution confirms these two factors to not just be 
passive players in endothelial homeostasis but master regulators of endothelial cell 
fate from a global perspective as well as in terms of organ heterogeneity. This global 
93 
 
dysregulation offers us a unique opportunity to tease out the multitude of different 
pathways that are regulated so as to maintain the multifaceted functionality that 
endothelial cells perform on a day to day basis.  
 
In conclusion, the unexpected finding that a combination of two 
transcription factors regulate endothelial cell fate in the adult mice has major 
implications for vascular biology. Given the catastrophic consequence of loss of 
both Erg and Fli1 in vascular integrity indicates that numerous 
pathophysiological conditions could emerge as a result of dysregulation of 
expression of these transcription factors. For example, post ischemic fibrosis, and 
endothelial to mesenchymal transitions could be driven in aberrant and 
maladapted downregulation of Fli1 and Erg.  
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Figure 3.14 Single cell analysis of Liver endothelial cells reveals complete 
segregation of Control and DKO ECs. (A) Resolution of single cell analysis into 8 
clusters (B) Segregation of samples into specific clusters reveals dominant control and 
KO clusters (C) Contribution of each sample to different clusters (D) Cluster 
distribution among the samples 
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Figure 3.15 Violin plots reveal specific genes segregate specifically to Control 
(0,1) and KO clusters (2,3,4). (A) Dominant expression of endothelial specific genes 
in Control cluster are downregulated in the DKO clusters (B) Specific genes related to 
mesenchymal fate and implicated in loss of endothelial cell fate are differentially 
expressed between the Control and KO clusters. 
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CHAPTER 4: CONCLUSIONS AND DISCUSSION 
 
The ETS family of transcription factors have been implicated extensively to 
play a role in endothelial and hematopoietic regulation (Randi et al., 2009; Sharrocks, 
2001). Here we investigated the role of Fli1, one of the key ETS factors that is 
expressed in both these lineages and showed that it is essential in maintaining key 
functions of both these cell types that are necessary for homeostasis. In Chapter 2, we 
focused on the understudied role of Fli1 in the hematopoietic stem cells and 
demonstrated that Fli1 is involved in critical mechanisms that regulate Hematopoietic 
and HSC homeostasis and function in adult mice. In Chapter 3, we elucidated the role 
of Fli1 in endothelial cells and showed that on its own Fli1 is not critical to maintain 
endothelial identity and function however it shares a significant overlap with one of its 
closely related ETS factors, Erg. We demonstrated that Fli1 and Erg synergize to 
maintain endothelial cell homeostasis and endothelial cell fate in adult mice. The 
biggest differentiating factor in these studies is the ability of Fli1 to regulate essential 
homeostatic functions in adult mice. A large number of genes have well defined roles 
during development but most of them are not actively involved in adult homeostasis 
and have redundancy with other factors due to which they are not essential in adults. 
We propose that Fli1 is a master regulator that directly regulates homeostatic 
processes in these two cell types which are overlooked in the context of regular 
physiology. 
 
4.1 FLI1 AND HEMATOPOIESIS 
 
 Early mouse models implicated a role for Fli1 in vascular integrity as well as 
platelet function due to developmental defects that were observed in global knockout 
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models. We demonstrated that this effect is mediated through expression of Fli1 in 
hemogenic endothelium and concurrently in the arising pre-HSCs that give rise to the 
hematopoietic system. Fli1 deletion in early AGM endothelial cells resulted in 
massive hemorrhage and defective hematopoiesis. AGM hematopoietic cells lacking 
Fli1 are unable to expand in vitro and are significantly reduced in overall numbers in 
Fli1∆EC/∆EC embryos. This effect carried over in the adult setting where inducing Fli1 
deletion caused complete bone marrow failure with peripheral blood counts going 
down in all three categories of WBCs, RBCs and platelets while platelet counts were 
most severely affected. Fli1 is unique in having an effect at every stage of 
hematopoietic differentiation from the HSC all the way down to terminally 
differentiated cell types such as erythrocytes and platelets.   
 
Another aspect that differentiates Fli1 in its function is its ability to orchestrate 
hematopoietic reconstitution. Through the various transplant experiments assessing 
lineage contribution and bone marrow engraftment, we demonstrated that absence of 
Fli1 is a significant impediment in achieving effective engraftment and subsequent 
differentiation to peripheral blood lineages. Fli1∆/∆ HSCs were defective in both 
primary and secondary transplant settings being unable to contribute to any peripheral 
blood lineage – B cell, T cell or myeloid lineages. Most importantly, we demonstrate 
that Fli1 is not only required in the context of hematopoietic reconstitution but for 
HSC homeostasis. During homeostasis, HSC contribution to hematopoiesis is 
minimal. The reduction in HSC numbers under homeostasis due to Fli1 deletion 
demonstrates the importance of the transcriptional activity of this ETS factor in HSCs. 
 
Given that this role for Fli1 has not been studied before in this context it might 
be a factor that is applicable in the context of bone marrow transplants from a clinical 
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perspective. Heterozygote deletion of Fli1 in Paris Trousseau syndrome suggests the 
possibility of a more advanced role of Fli1 in humans. Keeping that in mind, it would 
be interesting to assess Fli1 levels in clinical trials of cord blood or bone marrow 
transplants to see, on a very basic level if Fli1 confers an engraftment advantage. An 
ideal scenario correlating Fli1 expression with better probability of engraftment would 
enable early screening of transplants to ascertain successful engraftment even before 
administration. Fli1 is unique in being a transcription factor that regulates HSC 
activity during homeostasis. The most obvious implication for this is from the 
perspective of cancer or leukemia. If Fli1 downregulation can be used to modulate the 
expansion of leukemias the clinical applicability of this is limitless but this is where 
the omnipresent nature of this gene is a detriment. Clinical targeting of a factor that 
may lead to thrombocytopenia is less than ideal however there is always a work 
around for such situations. In this study, we have described two pathways – cKit and 
Mpl that address only a certain aspect of Fli1 function and so further research in 
understanding the other pathways involved in regulating leukemic expansion would be 
necessary to use Fli1 in a clinical setting. Additionally, screening small molecules that 
target specific functions of Fli1 are another alternative and a few compounds have 
already been identified that are able to downregulate Fli1 activity (Li et al., 2015; Li et 
al., 2012) 
 
 In conclusion, Fli1 is an essential factor in hematopoietic regulation during 
development and more importantly in adults. This study has merely scratched the 
surface of the various functions that Fli1 executes in the context of hematopoietic stem 
cell homeostasis. Further studies translating the role of Fli1 from the murine model to 
humans will allow us to tap into the unlimited potential of this master regulator of 
hematopoiesis. Identifying the functional aspect of Fli1 in HSC maintenance and self-
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renewal adds to the body of work implicating diverse functions of Fli1 in different 
hematopoietic cell types. The question remains as to how does Fli1 orchestrate this 
intricate transcriptional regulation in different cell types from HSCs to platelets to 
endothelial cells. Three aspects that may regulate this specificity may be – different 
isoforms, different binding partners and post translational modifications by signaling 
cascades in a cell type specific manner. The first aspect – isoforms though the easiest 
to identify through deep sequencing of Fli1 across various cell types is one of the 
hardest to prove in terms of cause and effect. Identification of different expression 
levels of isoforms need not imply functionality and will require both invitro 
overexpression studies as well as in vivo loss of function studies to understand the 
significance of this differential expression. This can prove difficult given functional 
overlap between isoforms and hence presents a significant challenge. 
 
 The second aspect focused on binding partners can be addressed through Co-
immunoprecipitation in a cell type specific manner to identify differences in the 
binding profile of Fli1. Furthermore, identifying important binding partners opens the 
possibility of studying the type of interaction between Fli1 and its partners, necessary 
to facilitate the cell specific transcriptional regulation. Lastly, post translational 
modifications (PTMs) can be identified by looking specifically at immunoprecipitated 
Fli1 and carrying out mass spectrometry to compare phosphorylation and other PTMs 
that may be cell type specific. All three of these aspects are interlinked and most likely 
contribute to the specificity of not just Fli1 but a number of different transcription 
factors. In conjunction with the genomic purview and the transcriptomic analysis for 
various cell types, Fli1 offers a unique opportunity to take a glimpse into the 
mechanisms governing transcriptional specificity for TFs. 
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4.2 FLI1 AND ENDOTHELIAL IDENTITY 
 
“One is only as young as one’s endothelium” 
-Anonymous 
 
 Our understanding of the various functions that endothelial cells perform has 
grown exponentially over the past few years. These cells are no longer just considered 
to be basic plumbing for the body, circulating essential nutrients and oxygen to 
various organs but orchestrate organ development, regeneration and are involved with 
regulation of different stem cell niches. Dysregulation of the endothelial cells can lead 
to aberrant fibrosis, malignancies and other non-physiological conditions. We sought 
to identify a factor that is essential in regulating endothelial cell fate. Endothelial cell 
fate is a term that encompasses all the functions of endothelial cells but at its core 
represents the basic functionality of endothelial cells and that is to maintain 
homeostasis through the expression of key surface markers such as VE-Cadherin, 
CD31 and VEGFR2. Our results here showed that Fli1, by itself is not essential for 
maintenance of this endothelial cell fate in the post AGM development, or the post-
natal retina or in adults. We demonstrate that this was due to redundancy with its 
closely related ETS family gene, Erg. Deletion of Fli1 and Erg resulted in lethality and 
we demonstrated that these two factors are essential for the maintenance of endothelial 
homeostasis and endothelial cell fate in adult mice. These observations are counter 
intuitive to our current understanding of endothelial biology since the majority of 
endothelial cells in adult vascular beds are quiescent and do not proliferate unless they 
are given a physiological insult or injury.  
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We identify two transcription factors that together regulate endothelial 
homeostasis and whose dysregulation is lethal to mice due to the complete loss of 
vascular integrity resulting in the formation of thrombi in the liver. Being able to 
observe this phenomenon in an in vitro setting gave us a better idea of the extent of 
cell fate loss in the endothelial cells. In vitro deletion demonstrated a drastic 
downregulation in VE-Cadherin, CD31 and VEGFR2 that can never be observed in 
vivo given the essential nature of their expression however the robust invitro system 
provides us with a platform to interrogate the various pathways that govern endothelial 
cell fate. The invitro system shows a consistent timeline for loss of key endothelial 
markers and enables us to test various pathways that may be involved in regulating 
key aspects of endothelial cell biology. The ability to live stain for markers such as 
VE-Cadherin and CD31 can allow us to conduct high content high throughput screens 
for multiple factors and pathways that may regulate endothelial cell fate. The recovery 
of these critical markers is just the first step in the level of functionality that Fli1 and 
Erg execute in endothelial cells. The second level would involve organ heterogeneity 
and being able to identify organ specific factors that enable endothelium in organ beds 
to respond appropriately so as to maintain homeostasis or facilitate repair and recovery 
in an organ. From a clinical standpoint, being able to address endothelial cell 
repertoire especially in the context of organ heterogeneity would enable us to decipher 
vascular cues that may regulate metastasis in specific vascular beds. Additionally, 
being able to understand the mechanisms that govern endothelial fate may improve 
our ability to culture endothelial cells which is currently challenging. Robust 
techniques for endothelial cell culture would allow us to step into the field of cell 
therapy. Endothelial cells by themselves, have been shown to provide radioprotection 
(Poulos et al., 2015) in transplant settings however the plasticity of endothelial cells 
allowing for direct differentiation to other cell types (Lis et al., 2017; Sandler et al., 
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2014) would open up infinite possibilities in terms of clinical applications for cell 
therapy. 
 
4.3 CONCLUDING REMARKS 
  
Genomic analysis is now available that allows us to compare the purview of 
Fli1 across multiple cells types from endothelial cells to megakaryocytes to 
hematopoietic stem and progenitors. Needless to say, the genomic accessibility of Fli1 
is different in different cell types and understanding the underlying mechanisms that 
govern this change is important to further enhance our understanding of what defines a 
certain cell type. Master regulators is a term that has been used to describe genes such 
as MyoD or Oct4 since their expression can be used to influence cell fate choices 
however this is a simplistic view of looking at gene regulation and does not factor in 
other environmental or cell autonomous cues that play a role in facilitating such 
transitions. If these factors were such effective master regulators then the efficiency of 
say iPS generation would be much higher compared to the low percentage conversion 
that is seen right now. It is here that the other factors influencing transcriptional 
regulation need to be studied in more detail. Leaving aside the obvious gene isoforms 
with different structure, there are two mechanisms that define context driven 
expression and those are binding partners and post translational modifications. 
Understanding these mechanisms in a cell type specific manner would open up the 
possibilities of efficient and effective direct conversion between cell types. What 
makes Fli1 an ideal candidate for these studies is its broad expression pattern with cell 
type specific function. Fli1 is expressed in fibroblasts, endothelial cells and almost all 
hematopoietic cell lineage except erythrocytes and it performs very different roles in 
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each of these cell types. Leveraging this to understand the mechanisms controlling 
Fli1 specificity is definitely an area that needs to be pursued in the future. 
 
The studies presented here demonstrate take the first steps in establishing the 
importance of Fli1 in the context of hematopoiesis and endothelial cell identity. In 
hematopoietic cells, we uncovered a novel mechanism implicating Fli1 with the 
regulation of hematopoietic stem cell homeostasis through two critical surface proteins 
– cKit and Mpl. In endothelial cells, we propose a novel concept that two transcription 
factors – Fli1 and Erg are involved in maintaining the fate of endothelial cells during 
homeostasis and their dysregulation results in a complete loss in identity of the 
endothelial cells. Future studies will be able to decipher the different mechanisms that 
govern this drastic loss in identity and disruption of homeostasis and its application in 
clinical settings as well as understanding the upstream signals that govern the 
specificity of the effect of these transcription factors in a cell type specific manner. 
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MATERIALS AND METHODS 
 
Mice  
VE-Cadherin cre mice were obtained from the labs of Dr Arispe and Dr Speck and 
were maintained on a C57Bl6 background. Fli1f/f mice were obtained from EMMA 
(ID:05992) as frozen embryos and rederived at the MSKCC Mouse Genetics core and 
maintained on a C57Bl6 background. C57BL/6J (CD45.2), B6.SJL-Ptprca Pepcb/BoyJ 
(CD45.1) and Rosa CreERT2 mice were obtained from Jackson laboratories. The 
breeding, maintenance and experimental procedures were performed in accordance 
with the guidelines of Institutional Animal Care and Use Committee of Weill Cornell 
Medical College. Genotyping was confirmed in the lab using genoptyping primers 
(Fli11-F CAGAGCCCTGGCTGTCTTGAACTCCTAGACCAG, Fli1-wt-R 
GGCGCTGTCGGACAGTAGTTCCAGGAGAAACTG, Fli1-del-R 
GTAGGGAATCCTACAATGATGAGACCCGTGTGCTG) and also sent to 
Transnetyx for offsite genotyping. 
 
Whole Mount staining 
Embryos were fixed in 4% PFA overnight and then washed twice in PBS before 
staining. Embryos were blocked in PBS with 5% milk, 5% serum and 0.1% Triton-X 
twice for 30’ at room temperature. Staining was carried out with Anti 
CD31(Biolegend MEC13.3) overnight followed by 5X washes with block solution for 
20’ at room temperature. Secondary staining was carried out overnight followed by 5X 
washes. Embryos were maintained in PBS before imaging on an LSM 710 Confocal 
Microscope (Zeiss). 
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Post-natal retina 
Retinas were collected at P6 and fixed overnight in 4% PFA. They were processed as 
described (Pitulescu et al., 2010) 
 
Hindlimb Ischemia  
The proximal part of the femoral artery and the bifurcation point between the popliteal 
artery and the saphenous artery of Fli1f/f mice were ligated and all side branches were 
dissected. The femoral artery was excised out via ligated points. With the muscle still 
exposed, 5x105 cells suspended in PBS were injected into the gracilis muscle. 
Hindlimb reperfusion was measured at indicated time points with laser Doppler 
perfusion imager (Persican PM3, Perimed). 
 
Isolation of early definitive pre-HSCs from AGM 
Embryos at E11.5 were used for AGM isolation and subsequent processing was 
carried out as described (Morgan et al., 2008) 
 
In vitro expansion of hematopoietic cells on E4-HUVEC platform 
Human umbilical vein endothelial cells (HUVECs) were isolated as described (Rafii et 
al., 1994) and cultured in endothelial cell growth medium – M199 (Sigma), 10% FBS 
(Omega Scientific), 50 μ g ml−1 endothelial mitogen (Alfa Aesar), and 100 μ g ml−1 
heparin (Sigma). Once endothelial cells were transduced with lentiviral vectors 
expressing E4ORF1 gene they were selected in Ex-vivo medium for two weeks and 
then cultured in human endothelial cell media and plated for expansion. Isolated 
cKit+Sca1+Lineage- (KLS) cells were plated on confluent 6-well for expansion in 
hematopoietic stem cell expansion medium – StemSpan SFEM (STEMCELL 
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Technologies) with 10% KnockOut Serum Replacement (Invitrogen), Glutamax and 
20mM HEPES (Invitrogen) 50 ng ml−1 mouse c-Kit ligand (SCF, Peprotech). 
 
Bone marrow transplantation and peripheral blood analysis 
For all transplant experiments, mice were irradiated with 950 cGy and transplanted 
with experiment specific bone marrow recovery dose. Peripheral blood and bone 
marrow analysis was performed at 4-week intervals with antibodies against c-
Kit/CD117 (2B8), Sca-1/Ly-6A (D7), CD48 (HM48-1), CD150 (mShad150), 
CD45.1(A20) and CD45.2 (104). Lineage antibody cocktail included: CD41 
(MWReg30), TER119 (TER119), B220 (RA3-6B2), CD11b (M1/70), Gr1 (RB6-8C5) 
and CD3 (17A2). DAPI was used to discriminate and eliminate dead cells from 
analysis. All antibodies were obtained from Biolegend unless mentioned. Peripheral 
blood was collected using retro-orbital bleeds in 1:1 ratio with PBS-EDTA (10mM). 
Blood was lysed using RBC lysis (Biolegend) and then analyzed for multilineage 
engraftment using above antibodies. 
 
Histology 
H&E staining of 12-mm paraffin sections was performed by Histoserv and imaged on 
a BX51 (Olympus) light microscope. 
 
Serum Analysis 
Retro-orbital bleeds were used to obtain 250µl of blood from mice before sacrificing. 
Blood was allowed to coagulate for an hour at room temperature. Cells were separated 
by a high-speed spin at 10,000 rpm for 1’. Supernatant was collected and submitted 
for serum analysis at the Histology Core at MSKCC. 
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Immunohistochemistry  
Mice were injected retro-orbitally with fluorescently labeled anti-VE-Cadherin 
antibody (BV13, Biolegend), 8 minutes prior to sacrifice. Harvested organs were fixed 
overnight in 4% PFA followed by 72 hours in 30% sucrose. Organs were embedded in 
O.C.T. (VWR). 16µm sections were counter stained with DAPI (Biolegend) and 
imaged on an LSM 710 Confocal Microscope (Zeiss). 
 
Peripheral Blood analysis  
Retro-orbital blood was collected on indicated days using heparinized capillary 
pipettes. A volume of 65µl blood was diluted in 195µl of PBS-EDTA (10µM) to 
prevent clotting. Complete blood counts and Differential blood counts were obtained 
with an automated Advia 120 (Siemens). 
 
Isolation of organ specific adult mouse endothelial cells 
Mice were injected retro-orbitally with 25μg of anti-VE-cadherin-AF647 antibody 
(BV13, Biolegend) 8 min prior to sacrifice and the organs were harvested. For flow 
cytometry and cell sorting, organs, including lungs, liver and heart were minced and 
incubated with collagenase A (25 mg ml−1), dispase II (25 mg ml−1), and DNase (250 
μg ml−1) (Roche) at 37 °C for 20–30 min to create a single-cell suspension. Cells were 
filtered through a 70μm filter immediately before counter staining. The single-cell 
suspension was blocked with anti-mouse CD16/32 (2.4G2) before antibody staining 
with anti-mouse CD31 PE-Cy7 (390, Biolegend), anti-mouse CD45 (30-F11) and anti-
mouse Podoplanin (8.1.1. Biolegend). Resulting adult mouse endothelial cell cultures 
were cultured on fibronectin-coated (Sigma-Aldrich) plates in mouse endothelial cell  
(mEC) media – DMEM:Ham’s F-12 (Sigma) supplemented with 20% FBS (Omega 
Scientific), 20 mM HEPES (Invitrogen), 100μg ml−1 heparin (Sigma), 50μg ml−1 
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endothelial mitogen (Alfa Aesar) and 5μM SB431542 (R&D, 1614). Purity of mECs 
and absence of contaminating hematopoietic cells were confirmed by flow cytometry 
and confocal microscopy. The same panel of antibodies was used for in vitro 
purification of primary endothelial cells that were isolated using CD31-captured 
(Biolegend MEC13.3) magnetic beads (Life Technologies).  
 
RNA isolation and sequencing 
At least 100 ng of total RNA from both freshly harvested and cultured cells was 
isolated (phenol-chloroform separation of TRIzol LS) and purified using Qiagen 
RNeasy Mini Kit. RNA quality was verified using an Agilent Technologies 2100 
Bioanalyzer. RNA library preps were prepared and multiplexed using Illumina TruSeq 
RNA Library Preparation Kit v2 (non-stranded and poly-A selection) and 10 nM of 
cDNA was used as input for high-throughput sequencing via Illumina’s HiSeq 4000 
producing 51 bp paired-end reads. Sequencing reads were demultiplexed (bcl2fastq 
v2.17), checked for quality (FastQC v0.11.5). Paired end reads were mapped against 
Mus Musculus reference genome GRCm38 v87 using Star aligner after the read 
quality control and trimming performed using Trimmomatic. Reads were counted to 
the reference gene annotations using htseq and the counts were analyzed and tested for 
differential using edgeR with plots and heatmaps made in R. 
 
ddSeq and Single Cell analysis 
A single cell suspension was loaded into the Bio-Rad ddSEQ Single-Cell Isolator on 
which cells were isolated, lysed and barcoded in droplets. Droplets were then 
disrupted and cDNA was pooled for second strand synthesis. Libraries were generated 
with direct tagmentation followed by 3’ enrichment and sample indexing using 
Illumina Nextera library prep kit. Pooled libraries were sequenced on the Illumina 
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NextSeq500 sequencer. Sequencing data were primarily analyzed using the SureCell 
RNA Single-Cell App in Illumina BaseSpace Sequence Hub. In particular, sequencing 
reads were aligned to reference genome using STAR aligner; cell barcodes were used 
to separate reads from different cells, and unique moledular identifiers (UMI) were 
used to remove duplicate reads that were actually derived from the same mRNA 
molecule. A knee plot was generated based on the number of UMI counts per cell 
barcode in order to identify “good” cells separating from empty beads or noise. A raw 
UMI counts table for each gene in each cell was then prepared. Seurat version 2.0.1 
was used for clustering analysis. We excluded cells with an outlier number of genes 
(4000) detected as potential multiplets. To mitigate the effects of cell cycle 
heterogeneity in data, we followed a previously published approach by assigning each 
cell a score based on its expression of canonical cell phase markers and then 
regressing these out. We also regressed out effects associated with number of UMIs 
and ribosomal gene content. A principle component analysis (PCA) was performed, 
where the top 16 principal components were selected for cell clustering and t-SNE 
projection. 
 
ChIP Analysis 
Anti-Fli1 or control Rabbit IgG (Ab46540) were used to identify Fli1-bound regions 
using a method based on detailed protocol report (Nolan et al., 2013). Cells (2–5X107) 
were fixed in 1% paraformaldehyde diluted in EC media. Fixation was quenched with 
125mM glycine and the cells were washed three times with PBS. After nuclei isolation 
and sonication using a Bioruptor, chromatin-protein complexes were incubated with 
10 mg antibody bound to Dynabeads (Invitrogen) overnight at 4°C under gentle 
agitation. Complexes were washed with PBS containing 0.5% BSA and 5mM EDTA 
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using magnetic separation and then DNA purified by phenol-chloroform extraction. 
Single read (50/50 bp) libraries were produced and then sequenced at the MSKCC 
Integrated Genomics Operation on Illumina HiSeq 4000. 
 
Statistical Analyses 
All data are presented as mean ± s.d. The data presented in the figures reflect multiple 
independent experiments performed on different days using different mice. The 
significance of differences was determined using a two-tailed Student’s t-test, unless 
otherwise stated. p > 0.05 was considered not significant; * p < 0.05; * * p < 0.01; * * 
* p < 0.001. In all the figures, n refers to the number of mice when applicable. All 
statistical analyses were performed using Graphpad Prism software. No animals were 
excluded from analyses.  
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